Professional Documents
Culture Documents
Guía de Precios PDF
Guía de Precios PDF
2014
Edited by
Julie E. Frye
Copyright © 2015 Management Sciences for Health, Inc.
Recommended citation: MSH (Management Sciences for Health). 2015. International Drug Price Indicator Guide, 2014
Edition. (Updated annually.) Medford, Mass.: MSH.
This publication was developed by Management Sciences for Health’s Center for Pharmaceutical Management,
Arlington, Virginia. The Guide is updated annually. The explanatory notes are in English, French, and Spanish and
the products and prices are in English. Comments and questions should be e-mailed to cpm@msh.org.
Note: All rights reserved. MSH has made every effort to ensure the accuracy of price, supplier, procurement agency
and other information presented in this publication. However, the reader’s attention is drawn to the introduction,
which describes the specific sources and limitations of information provided in this publication.
The reader’s attention is also drawn to the importance of quality assurance for pharmaceutical products. Licensing
authorities in the respective countries of manufacture are responsible for the review and approval of the detailed
composition and formulation when authorizing a pharmaceutical product to be marketed, including the specifica-
tions of its ingredients, as submitted by the manufacturer of the dosage form, and to oversee compliance with Good
Manufacturing Practice requirements as recommended by WHO.
MSH does not warrant that the products mentioned are in accordance with the national laws and regulations of any
country, including but not limited to patent laws. It is recommended that readers intending to use this publication
familiarize themselves with issues such as quality, safety and efficacy as well as quantification, patents, financial
stability and standing of the supplier, ability to supply the required quantities, delivery time, and other related
aspects.
This publication does not constitute an endorsement or warranty of the fitness of any product for a particular
purpose. This publication is not based on an active assessment of, and does not therefore constitute an acceptance or
recommendation in regard to, any product’s quality, safety, or efficacy.
This list may not be used by manufacturers and suppliers for commercial or promotional purposes. The mention of
specific companies and certain of their products does not imply that they are recommended by MSH in preference to
others of a similar nature that are not mentioned. Errors or omissions excepted, the names of propriety products are
distinguished by initial capital letters.
Bearing in mind that the data and information provided for a product depend largely on the supplier or procure-
ment agency, these data and information are being provided as is, and MSH makes no representations or warranties,
either express or implied, as to their accuracy, completeness, or fitness for a particular purpose. MSH accepts no
responsibility or liability for the reliance on, or use of, such data and information.
Nota: Todos los derechos reservados. MSH ha realizado todos los esfuerzos necesarios para asegurar la exactitud de
los precios, proveedores, agencias de adquisiciones y otra información presentada en esta publicación. Sin embargo,
se llama la atención del lector a la introducción que describe las fuentes específicas y las limitaciones de la información
proporcionada en esta publicación.
También se llama la atención del lector a la importancia del aseguramiento de la calidad para los productos
farmacéuticos. Las autoridades responsables de otorgar licencias en los respectivos países de fabricación son
responsables de la revisión y aprobación de la composición y formulación detallada al autorizar un producto
farmacéutico para su comercialización, incluyendo las especificaciones de los ingredientes, de acuerdo con la
información suministrada por el fabricante, así como de supervisar el cumplimiento con los requisitos de las Buenas
Prácticas de Fabricación recomendadas por la OMS.
MSH no garantiza que los productos mencionados están de acuerdo con las leyes y regulaciones nacionales de
ningún país, incluyendo pero no limitándose a las leyes de patentes. Se recomienda que los lectores que tengan la
intención de utilizar esta publicación se familiaricen con los aspectos relativos a la calidad, seguridad y eficacia así
como la cuantificación, los patentes, la estabilidad financiera y la situación del proveedor, su habilidad para
suministrar las cantidades requeridas, el tiempo de entrega y otros aspectos relacionados.
Esta publicación no constituye un respaldo o garantía con respecto a la idoneidad de cualquier producto para un fin
en particular. Esta publicación no está basada en una evaluación activa y por lo tanto no constituye una aceptación o
recomendación con respecto a la calidad, seguridad o eficacia de cualquier producto.
Esta lista no puede ser utilizada por los fabricantes y proveedores para fines comerciales o promocionales. La
mención de empresas específicas así como ciertos de sus productos no implica que estos están recomendados por
MSH con preferencia sobre otros productos de naturaleza similar que no hubieran sido mencionados. Salvo por
errores u omisiones, los nombres de los productos comerciales se distinguen con una letra mayúscula inicial.
Teniendo en mente que los datos y la información dados para un producto dependen en gran medida del proveedor
o de la agencia de adquisiciones, estos datos e información se suministran tal cuál están, y MSH no realiza ninguna
declación o garantía, ya sea expresa o implícita con respecto a la exactitud, integridad o idoneidad para un propósito
en particular. MSH no acepta responsabilidad alguna por la confianza depositada o el uso de dichos datos e
información.
Note: Tous droits réservés. MSH a cherché dans la mesure du possible à vérifier l’exactitude des données sur les prix,
les fournisseurs, les organismes d’achat et des autres informations présentées dans cette publication. Le lecteur n’en
est pas moins prié de se rapporter à l’introduction qui décrit les sources spécifiques et les limitations de l’information
donnée dans cette publication.
Le lecteur doit également prêter attention à l’importance de l’assurance de qualité pour les produits
pharmaceutiques. Les organismes chargés de la délivrance des autorisations dans les pays respectifs des fabricants
sont responsables de l’examen et de l’approbation de la composition et formulation détaillées avant d’autoriser la
mise sur le marché d’un produit donnée, notamment des spécifications des composants, tel qu’indiqué par le
fabricant dans la présentation et doivent par ailleurs s’assurer que sont observées les Bonnes pratiques de fabrication
recommandées par l’OMS.
MSH ne garantisse pas que les produits mentionnés soient conformes aux lois et réglementations nationales d’un
pays donné, notamment les lois relatives aux brevets. On recommande au lecteur qui souhaite utiliser cette publica-
tion de se mettre au courant des divers aspects tels que la qualité, l’innocuité et l’efficacité ainsi que la quantifications,
brevets, situation financière et réputation du fournisseur ainsi que sa capacité à fournir les quantités demandées dans
les bons délais.
La présente publication ne constitue pas une approbation ou recommandation de l’efficacité d’un produit dans un but
précis. Cette publication ne se fonde pas sur une évaluation active et ne constitue donc pas une acceptation ou
recommandation de la qualité, innocuité ou efficacité d’un produit.
Cette liste ne peut pas être utilisée par des fabricants ou fournisseurs à des fins commerciales ou promotionnelles. Si
certaines sociétés ou certains produits sont mentionnés, cela ne veut nullement dire qu’ils sont recommandés par
MSH de préférence à d’autres de nature analogue qui ne sont pas recommandés. Sauf erreur ou omission, les
marques déposées sont indiquées par des initiales en majuscule.
Sachant que les données et informations fournies sur un produit dépendent largement du fournisseur ou de
l’organisme chargé des achats, lesdites informations sont donc données telles quelles, sans que MSH ne fasse aucune
recommandation ou garantie, explicite ou implicite, quant à leur exactitude, intégralité ou adéquation dans tel but
donné. MSH n’accepte aucune responsabilité concernant la fiabilité ou l’utilisation des dites données et informations.
Editor
Julie E. Frye, Management Sciences for Health
Consulting Editor
Keith Johnson, Management Sciences for Health
Contributors
We thank MSH and WHO staff for their assistance with the International Drug Price Indicator
Guide. We also very much appreciate the information and cooperation we receive from the
suppliers included in the Guide. Finally, the tender data provided by government agencies
around the world greatly enhances the usefulness of the International Drug Price Indicator Guide,
and we thank the staff of the following organizations for their time and effort.
• Botswana Public Procurement and Asset Disposal Board
• La División Médica, la Gerencia de Operaciones y el Departamento de Farmacoterapia de la
Caja Costarricense de Seguro Social (“Costa Rica Social Security”)
• Clinton Health Access Initiative
• Democratic Republic of Congo Integrated Health Project (IHP)
• Dominican Republic PROMESE/CAL (“Central Support Unit for the Essential Medicines
Program”)
• Mission for Essential Medical Supplies (MEMS), Tanzania
• Namibia Ministry of Health and Social Services
• Organisation of Eastern Caribbean States Pharmaceutical Procurement Service, St. Lucia
• Ministerio de Salud del Perú (“Ministry of Health, Peru”)
• El Sistema de Integración Centroamericana (SICA) ("System of Central American Integra-
tion")
• South Africa Department of Health
• Sudan National Health Insurance Fund
Contents
ACRONYMS/ABREVIATURAS/SIGLES ................................................................................................................ ix
PREFACE .................................................................................................................................................................... E-3
Prólogo ............................................................................................................................................ S-3
Préface ............................................................................................................................................ F-3
LIST III: PRICE COMPARISON FORM (SUPPLIER PRICES ONLY) ............................ SP-1
Lista III: Formulario para la Comparación de Precios (Precios de Proveedores Solamente)
Liste III : Formulaire pour la Comparaison des Prix (Prix des Fournisseurs Seulement)
LIST III: PRICE COMPARISON FORM (BUYER PRICES ONLY) .................................. BP-1
Lista III: Formulario para la Comparación de Precios (Precios de Compradores Solamente)
Liste III : Formulaire pour la Comparaison des Prix (Prix des Acheteurs Seulement)
ANNEXES
List of Synonyms
WHO Essential Medicines List Therapeutic Categories
OMS Lista Modelo de Medicamentos Esenciales Categorías Terapéuticas
OMS Liste Modèle des Médicaments Essentiels Catégories Thérapeutiques
Acronyms/Abreviaturas/Sigles ix
GDF Global TB Drug Facility
GMP good manufacturing practices
buenas prácticas de manufactura
HIV human immunodeficiency virus
IC international (narcotics) control
control internacional de narcóticos
contrôle international (narcotiques)
INN international nonproprietary name
denominación común internacional
dénomination internationale
LME Lista de Medicamentos Esenciales [OMS]
Liste de Médicaments essentiels [OMS]
MOH Ministry of Health
MS ministère de la santé
MSH Management Sciences for Health
MSP ministerios de salud pública
N/D no disponible
NGO nongovernmental organization
OECS Organisation of Eastern Caribbean States
Organización de Estados del Caribe Oriental
Organisation des Etats de la Caraïbe de l’Est
OMS Organización Mundial de la Salud
Organisation mondiale de la Santé
ONG organizaciones no gubernamentales
organisations nongouvernementales
OPB organisations bénévoles privées
OVP organizaciones voluntarias privadas
P/D pas disponible
PPS Pharmaceutical Procurement Service
Servicio de Abastecimiento Farmacéutico
Service d’Approvisionnement pharmaceutique
SIDA síndrome de inmunodeficiencia adquirida
syndrome d’immunodéficience acquise
TU thousand units
miles de unidades
mille unités
UNFPA United Nations Population Fund
Fonds des Nations Unies pour la Population
USP United States Pharmacopeia
Farmacopea de los Estados Unidos
Pharmacopée des Etats Unis
VIH virus de la inmunodeficiencia humana
virus d’immunodéficience humaine
WHO World Health Organization
Preface E-3
Center for Pharmaceutical Management Policy, Access and Use Unit
Management Sciences for Health Department of Essential Medicines and Health
4301 North Fairfax Drive, Suite 400 Products
Arlington, VA 22203-1627 USA World Health Organization
Telephone: 1.703.524.6575 Avenue Appia 20
Fax: 1.703.524.7898 CH-1211 Geneva 27
E-mail: cpm@msh.org Switzerland
E-mail: forteg@who.int
Price Conversion
Prices in the International Drug Price Indicator Guide are listed in ascending order according to
unit price. All prices for the organizations listed below have been converted to U.S. dollars
(USD). The exchange rates used are for 1 July 2014 (http://www.oanda.com). Other catalogue
prices were listed originally in U.S. dollars and were not converted.
Currency (Organization Code) Exchange Rate (to USD)
British pound (DURBIN) 1.7126
Dominican Republic pesos (DOMREPUB) 0.0228
Euro (IDA, MEDEOR/EU) 1.3687
Ghanian New Cedi (CHAI) 0.3099
Indian Rupee (CHAI) 0.0166
Kenya shilling (MEDS) 0.0112
Namibian dollar (NAMIBIA) 0.0942
Nigerian Naira (CHAI) 0.0061
Peruvian nuevo sol (PERU) 0.3532
South African rand (SAFRICA) 0.0942
Sudanese pound (SUDANNHIF) 0.1746
Tanzanian shilling (MEDEOR/TZ, MEMS) 0.0006
Changes in exchange rates can cause costs to vary widely. The most current rate at the time of
your analysis should always be used when calculating drug costs.
Price Terms
The supplier prices and buyer prices in this Guide are based on different price terms, and so
must not be directly compared. The following incoterms are used to define the price types:
• CIF (cost, insurance, and freight): includes insurance and transport charges up to the port of
destination (sea shipments only)
Calculating Prices
When calculating and projecting real costs, it is important to consider factors such as financing,
delivery times, modes of transportation (air/sea/inland), and handling charges. An analysis of
these factors is beyond the scope and intent of this Guide. However, it is reasonable, for estima-
tion purposes, to add 10% for shipping costs to the listed price for suppliers in this Guide. The
buyer (government agency tender) prices listed generally do not require adjustment for ship-
ping charges.
Quality Assurance
We require all suppliers included in the International Drug Price Indicator Guide to complete a
quality assurance questionnaire. The purpose of the mandatory questionnaire is to help ensure
that the prices listed in this Guide are from reputable suppliers with established quality assur-
ance processes in place. The 28 questions address issues including inspection, testing, quality
assurance, licensing, recalls, quality control procedures, standards, and documentation. Al-
though this requirement provides some assurance of quality control processes, it does not
necessarily guarantee the quality of the products listed. Copies of the questionnaire can be
obtained from MSH on request.
The price sources included in the Guide have been screened only through the completeness of
the documents they have provided. This screening in no way constitutes an in-depth review of
product quality. Inclusion in the Guide does not constitute pre-qualification or approval of any
sort by MSH and WHO.
Product Quality
The suppliers and agencies selected for this Guide are not manufacturers, but they offer prod-
ucts that are stated to be in compliance with international quality standards specified by organi-
zations such as the United States Pharmacopeia (USP), the British Pharmacopoeia (BP), and the
European Pharmacopoeia (EP). All suppliers in this guide state that the manufacturing plants
with which they work maintain high quality standards by having in place on-site quality assur-
ance systems in order to ensure that all products are complying with WHO Good Manufactur-
ing Practices (GMP) and with government regulations. Quality certificates in line with the
ATC/DDD System1
Drug utilization data have a central role in the quality of care cycle and are essential to the
management of policy related to drug supply, pricing, cost, and use. The anatomical therapeutic
chemical (ATC) and defined daily dose (DDD) methodologies for classification and measure-
ment can be helpful in following and comparing cost trends, but need to be used with caution.
Basing detailed reimbursement, therapeutic group reference pricing, and other specific pricing
decisions on the ATC and DDD assignments is a misuse of the system.
The purpose of the ATC/DDD system is to serve as a tool for drug utilization research in order
to improve drug use practices. One component of this is the presentation and comparison of
drug consumption statistics at international and other levels.
A major aim of the WHO Collaborating Centre for Drug Statistics Methodology and Working
Group is to maintain stable ATC codes and DDDs over time to allow trends in drug consump-
tion to be studied without the complication of frequent changes to the system. There is a strong
reluctance to make changes to classifications or DDDs when such changes are requested for
reasons not directly related to drug consumption studies. For this reason the ATC/DDD system
by itself is not suitable for guiding decisions about reimbursement, pricing, and therapeutic
substitution.
The classification of a substance in the ATC/DDD system is not a recommendation for use, nor
does it imply any judgments about efficacy or relative efficacy of drugs and groups of drugs.
Text in this section is adapted from the WHO Collaborating Centre for Drug Statistics Methodology website (http://
1
www.whocc.no/atcddd/).
Date of Handling
Supplier Code Price Type Details
List Fee
Prices are effective until publication of revised price list. Transport costs
MEDEOR/ September are charged individually according to expenses. Special packaging in cases
Action Medeor 1% EXW Tönisvorst
EU 2014 costs Euro 26 per case. Minimum handling fee is Euro 50. Only serves non-
profit organizations.
Action Medeor International Healthcare is a not-for profit procurement
agency founded in 2004 and owned by Action Medeor. It supplies the not-
Action Medeor
MEDEOR/ September for-profit market (primarily in Tanzania) and does not supply to individuals
International 0% EXW
TZ 2014 or commercial pharmacies. A 3.5% service charge applies for all non-
Healthare
Tanzanian customers to cover bank charges and currency loss. No
minimum quantities are required.
AMSTEL- January EXW Lelystad, Amstelfarma prices are given as an indication only. There are no minimum
Amstelfarma 0%
FARM 2015 The Netherlands orders required or service charges.
ASRAMES (Association Régionale d'Approvisionnement en Médicaments
August DDP or CIP Essentiels) only serves organizations in the DRC that have been recognized
ASRAMES ASRAMES 0%
2014 Kinshasa by the Ministry of Health as a health institution or as an NGO working in
the health sector.
Durbin supplies pharmaceuticals and medical supplies to doctors,
EXW United pharmacies, hospitals, pharmaceutical wholesalers and traders, military and
Durbin PLC DURBIN 2013-2014 0%
Kingdom government agencies, charities and other relief organisations worldwide.
Minimum order UK £100.
E-10
List Fee
Since 1972, the IDA Foundation has been committed to improving access
to and delivering high-quality essential medicines and medical supplies to
low- and medium-income countries. As an independent and self-supporting
November
IDA Foundation IDA 1.5% FCA Amsterdam foundation, IDA distributes more than 3,000 products to over 100
2014
countries worldwide. Minimum order of Euro 1500. Orders under Euro
5,000 are charged a handling fee of 3%. Orders over Euro 5,000 are
charged a handling fee of 1.5%. Prices are indicative and may change.
January FCA Lelystad,
IMRES IMRES 0% Minimum order quantity is US$1250.
2015 The Netherlands
Medical Export November FCA Gorinchem, Prices are given as an indication only. There are no minimum orders
MEG 0%
Group 2014 The Netherlands required or service charges.
MSD sales prices are valid for all governmental health facilities, approved
Medical Stores NGOs, mission hospitals, charitable hospitals and other health care
International
Date of Handling
Development Code Price Type Details
List Fee
Organization
The Global Drug Facility (GDF) is a mechanism to expand access to, and
availability of, high-quality anti-TB drugs to facilitate global expansion and
maintenance of DOTS, the internationally recommended strategy to
control tuberculosis. Drugs are supplied through free grants, but are also
available for purchase by governments and organizations wishing to take
advantage of the quality, prices, and technical support offered through the
GDF Direct Procurement Service. GDF performs compulsory independent
testing of each batch of drugs it supplies and pre-shipment inspection of
Global TB Drug EXW Supplier each order it delivers to confirm high quality.
GDF 2014 0%
Facility Factory
To facilitate the efficient delivery of products, GDF uses procurement
agents. Prices include the cost of the product as well as quality control
costs and a GDF procurement agent fee. Costs for pre-shipment
inspection, transport (air freight or sea freight) and insurance, are not
included in the listed product prices. GDF sends a team of TB and drug
management experts to the country four months after drugs arrive, to
assess drug usage and provide any needed technical assistance. GDF does
not charge for its technical assistance to countries.
E-11
E-12
International
Date of Handling
Development Code Price Type Details
List Fee
Organization
UNFPA conducts annual tenders to purchase goods for their field offices
and on behalf of external clients in more than 168 countries, mainly in the
September developing world. UNFPA serves only governments and nonprofit
UN Population Fund UNFPA 5% FOB
2014 organizations. UNFPA charges a 5% administration fee to non-UNFPA
buyers. There is a minimum order requirement of US$5,000 per item.
Prices are indicative and may change.
Approx.
Date of Price Value of
Buyer Code Details
List Type Tender
(USD)
The Public Procurement and Asset Disposal Board of
Botswana Public Procurement and January
BOTSWANA N/A N/A Botswana conducts open and closed domestic and
Asset Disposal Board 2014
international tenders on a regular basis.
Costa Rica Social Security conducts an annual, open,
126
Caja Costarricense de Seguro Social CRSS 2014 DDU international tender and negotiates contracts for drugs and
million
medical supplies for its own facilities.
Telephone: 49.21.56.97.88.0
Fax: 49.21.56.97.88.88
E-mail: info@medeor.org
URL: http://www.medeor.org
Telephone: 49.21.56.97.88.0
Fax: 49.21.56.97.88.88
E-mail: medeortz@bol.co.tz
URL: http://www.medeor.org
Amstelfarma
Nijverheidsweg 37
2102LK Heemstede
THE NETHERLANDS
Telephone: 31-23-5484040
E-mail: sales@amstelfarma.com
URL: http://www.amstelfarma.nl
Telephone: 243.9.98.08.81.70
E-mail: info@asrames.org
URL: www.asrames.com
Telephone: 506.222.1878
Fax: 506.257.7004
E-mail: farmaco@ccss.sa.cr
URL: http://www.info.ccss.sa.cr/
Telephone: 617.774.0110
E-mail: info@clintonhealthaccess.org
URL: http://www.clintonhealthaccess.org
Telephone: 243.99.930.1015
URL: http://www.msh.org/our-work/projects/integrated-health-project
Telephone: 809.518.1313
E-mail: promesecal@promesecal.gov.do
URL: http://www.promesecal.gov.do/
Durbin PLC
180 Northolt Road
South Harrow
Middlesex
HA2 0LT
UNITED KINGDOM
Telephone: 44.20.8660.2220
Fax: 44.20.8668.0751
E-mail: cataloguesales@durbin.co.uk
URL: http://www.durbin.co.uk
Telephone: 41.22.791.3647
Fax: 41.22.791.4886
E-mail: gdf@who.int
URL: http://www.globaldrugfacility.org or http://www.stoptb.org/GDF
Telephone: 31.20.40.33.051
Fax: 31.20.40.31.854
E-mail: info@idafoundation.org
URL: http://www.idafoundation.org
IMRES
P.O. Box 214
8200 AE Lelystad
THE NETHERLANDS
Telephone: 31.320.296969
Fax: 31.320.296929
E-mail: info@imres.nl
URL: http://www.imres.nl
Telephone: 31.183.356.100
Fax: 31.183.356.122
E-mail: sales@meg.nl
URL: http://www.meg.nl
Telephone: 255.22.2860890
Fax: 255.22.2865814
E-mail: info@msd.or.tz
URL: http://www.msd.or.tz
Telephone: 255.27.250.9366
Fax: 255.27.254.4908
E-mail: info@mems.or.tz
Telephone: 254.020.3920.404
Fax: 254.020.3920.600
E-mail: customerservice@meds.or.ke
URL: http://www.meds.or.ke
Phone: 264.61.233151
Fax: 264.61.238746
URL: http://www.cms-namibia.com
Telephone: 758.452.5895
Fax: 758.453.0227
E-mail: pps@oecs.org
URL: http://www.oecs.org/pps/
Telephone: 51.14.315.6600
E-mail: webmaster@minsa.gob.pe
URL: http://www.minsa.gob.pe/portada/
Telephone: 27.12.312.0000
Fax: 27.12.326.4395
URL: http://www.doh.gov.za
Telephone: 1.571.227.8600
Fax: 1.571.227.8601
URL: http://www.pfscm.org
Telephone: 45.3546.7000
Fax: 45.3546.7018
E-mail: accessrh@unfpa.org
URL: http://www.unfpa.org/public/supplies
Item Description
The item description includes the generic name, strength, dosage form, and the route of admin-
istration. If the product has two widely used names (for example, vitamin C and ascorbic acid),
one name will appear in brackets. See the List of Synonyms in the Annex.
IC
Products under international narcotics control are identified with (IC) next to the de-
scription.
Nomenclature
International nonproprietary names (INNs) have been used for the list of drugs in this
Guide. If an INN has not been assigned, the most common generic name has been used.
Drug dosage forms listed are generally those included in the World Health
Organization’s 19th Model List of Essential Medicines (revised April 2015), found at
http://www.who.int/medicines.
Route of Administration
Routes of administration are coded as follows:
Item Type Code
Condoms COND
Diagnostic Strips and Tests and Lab Supplies DIAG
Ear Preparations OTIC
Eye Preparations OPHT
Injectable Medicines INJ
Intrauterine Device (IUD) IUD
Intravenous Solutions IV
Medicines for Inhalation INH
Medicines for Nasal and Throat Use N/T
Subcutaneous Medicines S/C
Sublingual Tablets SL
Suppositories/Enemas/Rectal Ointment RECT
Tablets/Capsules/Oral Liquids PO
Topical Medicines (liquids, powders, creams, ointments) TOP
Vaginal Preparations VAG
Not Applicable N/A
Package
Package sizes are provided by the suppliers and buyers.
DDD
The DDD is the assumed average maintenance dose per day for a drug used for its main indica-
tion in adults. The defined daily dose is a unit of measurement and does not necessarily reflect
the recommended or prescribed daily dose. Doses for individual patients and patient groups
will often differ from the DDD and will necessarily be based on individual characteristics (e.g.,
WHO EML
The “WHO EML” column indicates whether the product is included on the 2015 WHO Model
List of Essential Medicines. We identify five categories in the International Drug Price Indicator
Guide:
E = On the WHO core list in the same dosage form and strength
C = On the WHO complementary list in the same dosage form and strength
P = On the WHO list, but in a different presentation (different dosage form and/or
strength)
T = Not on the WHO list, but can be an alternative for an item listed as a
therapeutic group example
N = Not on the WHO model list
ATC Code
The ATC code is the anatomical therapeutic chemical classification code assigned by the WHO
Collaborating Centre for Drug Statistics Methodology. The purpose of the ATC/DDD system is
to serve as a tool for drug utilization research in order to improve drug use practices. One
component of this is the presentation and comparison of drug consumption statistics at interna-
tional and other levels.
In the ATC classification system, the drugs are divided into different groups according to the
organ or system on which they act and their chemical, pharmacological, and therapeutic proper-
ties. Drugs are classified in groups at five different levels. The drugs are divided into 14 main
groups (1st level), with one pharmacological/therapeutic subgroup (2nd level). The 3rd and 4th
levels are chemical/pharmacological/therapeutic subgroups, and the 5th level is the chemical
substance.2
2
Adapted from the WHO Collaborating Centre for Drug Statistics Methodology website at http://www.whocc.no/
atcddd/.
High/Low Ratio
The high/low ratio compares the highest unit price with the lowest unit price. For example, a
high/low ratio of 3 means that the highest unit price is three times greater than the lowest unit
price.
3
For further discussion, see Statistics without Tears—A Primer for Non-Mathematicians, by Derek Rowntree (New York: Charles
Scribner’s Sons, 1981), pp. 41–45.
Item Description
The item description includes the generic name, strength, dosage form, and the route of admin-
istration. If the product has two widely used names (for example, vitamin C and ascorbic acid),
one name will appear in brackets. See the List of Synonyms in the Annex.
IC
Products under international narcotics control are identified with (IC) next to the de-
scription.
Nomenclature
International nonproprietary names have been used for the list of drugs in this Guide. If
an INN has not been assigned, the most common generic name has been used. Drug
dosage forms listed are generally those included in the World Health Organization’s 19th
Model List of Essential Medicines (revised April 2015), found at http://www.who.int/
medicines.
Route of Administration
Routes of administration are coded as follows:
Item Type Code
Condoms COND
Diagnostic Strips and Tests and Lab Supplies DIAG
Ear Preparations OTIC
Eye Preparations OPHT
Injectable Medicines INJ
Intrauterine Device (IUD) IUD
Intravenous Solutions IV
Medicines for Inhalation INH
WHO EML
The “WHO EML” column indicates whether the product is included on the 2015 WHO Model
List of Essential Medicines. We identify five categories in the International Drug Price Indicator
Guide:
E = On the WHO core list in the same dosage form and strength
C = On the WHO complementary list in the same dosage form and strength
P = On the WHO list, but in a different presentation (different dosage form and/or
strength)
T = Not on the WHO list, but can be an alternative for an item listed as a
therapeutic group example
N = Not on the WHO model list
Number of Suppliers/Buyers
The number of suppliers or buyers offering this product.
Median Price
When using the Guide for comparison with local prices, or for estimating the total value of a
proposed procurement list, an average price can be helpful. There are basically two kinds of
average prices that could be used: the mean price and the median price. The mean price is the
simple average of all prices shown for a drug; the values are added up and divided by the
number of values.
However, there is a problem when one or two prices are much higher or lower than the rest for
a certain drug. These “outliers” skew the mean and make it less representative. For example, in
a series of seven values such as $1, $2, $2, $3, $5, $16, $20, the total of all the values is $49, and
dividing by seven gives a mean value of $7. For comparison or estimation purposes, it is likely
that this average is too high, due to the two prices that are much higher than others in the series.
To avoid this risk, we use the median price.
The median price is a type of average; it is the value that splits a series of values in half when
the series is put in ascending order. This is likely to be a more valuable approach for estimating
actual future prices (or for comparing with local prices) when there is a skewed distribution.
If there is an odd number of values in the series, as in the example above, the median value is
the middle value in the series ($3 in the example). When there is an even number of values in a
Highest Price
The highest price from listed suppliers and buyers.
Lowest Price
The lowest price from listed suppliers and buyers.
High/Low Ratio
The high/low ratio compares the highest unit price with the lowest unit price. For example, a
high/low ratio of 3 means that the highest unit price is three times greater than the lowest unit
price.
DDD
The DDD is the assumed average maintenance dose per day for a drug used for its main indica-
tion in adults. The defined daily dose is a unit of measurement and does not necessarily reflect
the recommended or prescribed daily dose. Doses for individual patients and patient groups
will often differ from the DDD and will necessarily be based on individual characteristics (e.g.,
age and weight) and pharmacokinetic considerations.
Drug consumption data presented in DDDs give only a rough estimate of consumption and not
an exact picture of actual use. DDDs provide a fixed unit of measurement independent of price
and formulation, enabling the researcher to assess trends in drug consumption and to perform
comparisons between population groups.
The defined daily doses are from the WHO Collaborating Centre for Drug Statistics Methodol-
ogy. They are illustrative defined daily doses, as recommended by the World Health
Organization’s Drug Utilization Research Group (DURG). Not all drugs listed in this price
comparison guide have defined daily doses assigned by this method. A DDD will only be
assigned for drugs that already have an ATC code.
The main use of the DDD is for estimating drug consumption, based on inventory/distribution
data. This estimate can be combined with price information for budgeting purposes.
Note: The defined daily dose should not be used for dosing or therapeutic determinations. Refer to
prescribing information for dosing schedules for specific indications.
4
For further discussion, see Statistics without Tears—A Primer for Non-Mathematicians, by Derek Rowntree (New
York: Charles Scribner’s Sons, 1981), pp. 41–45.
Item Description
The item description includes the generic name, strength, dosage form, and the route of admin-
istration. If the product has two widely used names (for example, vitamin C and ascorbic acid),
one name will appear in brackets. See the List of Synonyms in the Annex.
IC
Products under international narcotics control are identified with (IC) next to the de-
scription.
Nomenclature
International nonproprietary names have been used as the basis for the list of drugs in
this Guide. If an INN has not been assigned, the most common generic name has been
used. Drug dosage forms listed are generally those included in the World Health
Organization’s 19th Model List of Essential Medicines (revised April 2015), found at
http://www.who.int/medicines.
WHO EML
The “WHO EML” column indicates whether the product is included on the 2015 WHO Model
List of Essential Medicines. We identify five categories in the International Drug Price Indicator
Guide:
E = On the WHO core list in the same dosage form and strength
C = On the WHO complementary list in the same dosage form and strength
P = On the WHO list but in a different presentation (different dosage form and/or
strength)
T = Not on the WHO list, but can be an alternative for an item listed as a
therapeutic group example
N = Not on the WHO model list
Pack Size
The blank here is for the user to enter his or her purchase pack size.
Pack Price
This blank is for the user to enter the price for the purchase pack entered in the previous blank.
The median price is a type of average; it is whatever value splits a series of values in half when
the series is put in ascending order. If there is an odd number of values in the series, the median
value is the middle value in the series. This is likely to be more valuable for estimating actual
future prices (or comparing with local prices), when there is a skewed distribution.
When there is an even number of values in a series, such as the series $1, $3, $4, $6, $14, $20, the
median is calculated by averaging the two middle values. In this example, the median is the
average of $4 and $6, which is $5. Again, this is likely to be closer to reality for comparison or
estimation than the arithmetic mean of $8 ($48 divided by 6).5
5
For further discussion, see Statistics without Tears—A Primer for Non-Mathematicians, by Derek Rowntree (New York: Charles
Scribner’s Sons, 1981), pp. 41–45.
Prólogo S-3
Favor de tomar nota que se puede encontrar una versión electrónica de la Guía Internacional
de Indicadores de Precios de Medicamentos en el Centro de Recursos Electrónicos de MSH en
http://erc.msh.org/priceguide.
Para obtener más información o para hacer comentarios o sugerencias sobre el formato del
contenido de esta publicación, póngase en contacto con nosotros en:
Center for Pharmaceutical Management Policy, Access and Use Unit
Management Sciences for Health Department of Essential Medicines and Health
4301 North Fairfax Drive, Suite 400 Products
Arlington, VA 22203-1627 USA World Health Organization
Teléfono: 1.703.524.6575 Avenue Appia 20
Fax: 1.703.524.7898 CH-1211 Geneva 27
Correo electrónico: cpm@msh.org Switzerland
Correo electrónico: forteg@who.int
Conversión de precios
Los precios que figuran en la Guía Internacional de Indicadores de Precios de Medicamentos
están en orden ascendente conforme al precio unitario. Todos los precios obtenidos por las
organizaciones señaladas a continuación han sido convertidos a dólares estadounidenses. Los
tipos de cambio utilizados son los que regían el 1 de julio de 2014 (http://www.oanda.com).
Los demás precios del catálogo ya estaban originalmente en dólares estadounidenses, por lo
que no se convirtieron.
Moneda (Codigo de agencia) Tipo de cambio (a $EE.UU.)
Chelín de Kenia (MEDS) 0.0112
Chelín de Tanzania (MEDEOR/TZ, MEMS) 0.0006
Dólar de Namibia (NAMIBIA) 0.0942
Euro (IDA, MEDEOR/EU) 1.3687
Libra esterlina (DURBIN) 1.7126
Libra sudanesa (SUDANNHIF) 0.1746
Naira nigeriano (CHAI) 0.0061
Nuevo cedi de Ghana (CHAI) 0.3099
Nuevo sol de Perú (PERU) 0.3532
Pesos de la República Dominicana (DOMREP) 0.0228
Rand sudafricano (SAFRICA) 0.0942
Rupia india (CHAI) 0.0166
Las fluctuaciones en los tipos de cambio pueden hacer variar considerablemente los costos.
Siempre deberá usar el tipo de cambio más reciente cuando haga su análisis para calcular los
costos de los medicamentos.
Garantía de calidad
Nosotros requerimos que todos los proveedores que figuran en la Guía Internacional de
Indicadores de Precios de Medicamentos llenen un cuestionario sobre garantía de calidad. El
propósito de llenar este cuestionario obligatorio es ayudar a asegurar que los precios cotizados
en esta Guía provengan de proveedores de reputación con procesos de garantía de calidad
debidamente instalados. Las 28 preguntas trata de asuntos como inspección, prueba, garantía
de calidad, concesión de licencias, retirada de productos del mercado, procedimientos de
control de calidad, estándares y documentación. Aunque este requisito brinda cierta garantía
en cuanto a los procesos de control de calidad, no necesariamente garantiza la calidad de los
productos ofrecidos. Se pueden obtener copias del cuestionario solicitándolas de Management
Sciences for Health.
Sistema ATC/DDD1
Los datos sobre la utilización de medicamentos desempeñan un papel muy importante en la
calidad del ciclo de atención y son esenciales para administrar la política relacionada con el
suministro, fijación de precios, costo y uso de los medicamentos. El sistema de clasificación
anatómica-terapéutica-química (ATC) y la unidad de medida técnica llamada la dosis diaria
definida (DDD) pueden proveer metodologías útiles para el seguimiento y la comparación de
las tendencias en el costo, pero se deben usar con cautela. Basar el reembolso detallado, la
fijación de precios de referencia de grupos terapéuticos y otras decisiones específicas sobre
precios en las clasificaciones asignadas por el sistema ATC/DDD, es una utilización errónea del
mismo.
El sistema ATC/DDD tiene por objeto servir de herramienta para investigar la utilización de
medicamentos a fin de mejorar la calidad del uso de esos medicamentos. Uno de sus
componentes es la presentación y comparación de las estadísticas sobre consumo de
medicamentos al nivel internacional y a otros niveles.
Una de las principales aspiraciones del Collaborating Centre for Drug Statistics Methodology y
Working Group de la OMS es mantener códigos de ATC y DDD estables con el transcurso del
tiempo a fin de poder estudiar las tendencias en el consumo de los medicamentos sin la
complicación de cambios frecuentes al sistema. Existe una renuencia muy grande a hacer
1
El texto de esta sección fue tomado del sitio del Collaborating Centre for Drug Statistics Methodology de la OMS en la Web
en http://www.whocc.no/atcddd/.
Action Medeor International Healthcare es una agencia de compras sin fines de lucro,
fundada en 2004, que pertenece a Action Medeor. Abastece al mercado sin fines de
Action Medeor
MEDEOR/ septiembre lucro (principalmente Tanzania) y no abastece a individuos o a farmacias comerciales.
International 0% EXW
TZ 2014 Se aplica un 3,5% de recargo por servicios a todos los clientes que no son de
Healthare
Tanzania para cubrir cobros bancarios y pérdidas por cambio de moneda. No se
requieren cantidades mínimas.
EXW
S-12
ellas y por otras organizaciones. Las organizaciones listadas en la Guía son:
Organización
para el Fecha da Cargo por Tipo de
Código Detalles
desarrollo la lista manejo precio
internacional
Los medicamentos se adquieren como donativos gratuitos, pero también se ofrecen para la
venta a gobiernos y organizaciones que desean valerse de la calidad, los precios y asistencia
técnica/apoyo para la gestión de medicamentos que se ofrece a través del Servicio Directo de
Adquisiciones GDF. El Servicio Mundial de Medicamentos Contra la Tuberculosis (GDF por
sus siglas en Ingles) efectúa pruebas independientes obligatorias de cada lote de medicamentos
que suministra, e inspecciones pre-embarque de cada orden que despacha para asegurar la más
El Servicio
alta calidad. Además del costo de los medicamentos, los costos del control de calidad son
Mundial de
pagados por el cliente (o por el GDF, en el caso de una donación).
Medicamentos
Contra la GDF 2014 0% EXW
El GDF utiliza agentes de compra para asegurar la entrega eficiente de los productos. Un cargo
Tuberculosis por los servicios de compra es agregado al costo de la orden, que incluye el costo de los
(Global TB medicamentos, el de control de calidad y el de transporte. GDF envía al país un equipo de
Drug Facility) expertos en tuberculosis y en gestión de medicamentos 4 meses después del arribo de los
medicamentos, para evaluar su uso y proporcionar la asistencia técnica que fuera requerida.
Esta asistencia técnica del GDF a los países no tiene ningún costo. La GDF es un mecanismo
para ampliar el acceso a, y la disponibilidad de, medicamentos de alta calidad contra la TB para
facilitar la ampliación mundial del tratamiento directamente observado, a corto plazo (DOTS),
la estrategia internacionalmente recomendada para el control de la tuberculosis.
S-14
libres. Estos son los precios reales obtenidos por las organizaciones listadas y se incluyen con fines de comparación solamente.
No se pueden colocar pedidos con ninguna de estas organizaciones.
Valor
Fecha Tipo
aprox. de la
Comprador Código de la de Detalles
licitación
lista precio
(USD)
febrero y
El Ministerio de Salud del Perú celebra anualmente una licitación
Perú Ministerio de Salud PERU abril DDP 197 millión
nacional y abierta para productos farmacéuticos e insumos médicos.
2014
El Sistema de Integración Centroamericana (SICA) celebra
El Sistema de Integración agosto
SICA CIF 4,2 millión anualmente una licitación internacional y cerrada para un grupo de
Centroamericana (SICA) 2014
medicamentos seleccionados.
El Departmento de Salud de Sudáfrica celebra las licitaciónes
South Africa Department of Health SAFRICA 2014 DDP N/D nacionales y abiertos para productos farmacéuticos e insumos
médicos cada dos años.
El Fondo de Seguro Nacional de Salud de Sudán celebra anualmente
Sudan National Health Insurance SUDAN- junio
DDP 16,8 millión las licitaciónes nacionals y abiertas para productos farmacéuticos e
Fund NHIF 2014
insumos médicos.
Teléfono: 49.21.56.97.88.0
Fax: 49.21.56.97.88.88
Correo electrónico: info@medeor.org
URL: http://www.medeor.org
Teléfono: 49.21.56.97.88.0
Fax: 49.21.56.97.88.88
Correo electrónico: medeortz@bol.co.tz
URL: http://www.medeor.org
Amstelfarma
Nijverheidsweg 37
2102LK Heemstede
THE NETHERLANDS
Teléfono: 31-23-5484040
Correo electrónico: sales@amstelfarma.com
URL: http://www.amstelfarma.nl
Teléfono: 243.9.98.08.81.70
Correo electrónico: info@asrames.org
URL: www.asrames.com
Teléfono: 506.222.1878
Fax: 506.257.7004
Correo electrónico: farmaco@ccss.sa.cr
URL: http://www.info.ccss.sa.cr/
Teléfono: 617.774.0110
Correo electrónico: info@clintonhealthaccess.org
URL: http://www.clintonhealthaccess.org
Teléfono: 243.99.930.1015
URL: http://www.msh.org/our-work/projects/integrated-health-project
Teléfono: 809.518.1313
Correo electrónico: promesecal@promesecal.gov.do
URL: http://www.promesecal.gov.do/
Durbin PLC
180 Northolt Road
South Harrow
Middlesex
HA2 0LT
UNITED KINGDOM
Teléfono: 44.20.8660.2220
Fax: 44.20.8668.0751
Correo electrónico: cataloguesales@durbin.co.uk
URL: http://www.durbin.co.uk
Teléfono: 41.22.791.3647
Fax: 41.22.791.4886
Correo electrónico: gdf@who.int
URL: http://www.globaldrugfacility.org o http://www.stoptb.org/GDF
Teléfono: 31.20.40.33.051
Fax: 31.20.40.31.854
Correo electrónico: info@idafoundation.org
URL: http://www.idafoundation.org
IMRES
P.O. Box 214
8200 AE Lelystad
THE NETHERLANDS
Teléfono: 31.320.296969
Fax: 31.320.296929
Correo electrónico: info@imres.nl
URL: http://www.imres.nl
Teléfono: 31.183.356.100
Fax: 31.183.356.122
Correo electrónico: info@meg.nl
URL: http://www.meg.nl
Telephone: 255.22.2860890
Fax: 255.22.2865814
E-mail: info@msd.or.tz
URL: http://www.msd.or.tz
Teléfono: 255.27.250.9366
Fax: 255.27.254.4908
Correo electrónico: info@mems.or.tz
Teléfono: 254.020.3920.404
Fax: 254.020.3920.600
Correo electrónico: customerservice@meds.or.ke
URL: http://www.meds.or.ke
Teléfono: 264.61.233151
Fax: 264.61.238746
URL: http://www.cms-namibia.com
Teléfono: 758.452.5895
Fax: 758.453.0227
Correo electrónico: pps@oecs.org
URL: http://www.oecs.org/pps/
Teléfono: 51.14.315.6600
Correo electrónico: webmaster@minsa.gob.pe
URL: http://www.minsa.gob.pe/portada/
Teléfono: 27.12.312.0000
Fax: 27.12.326.4395
URL: http://www.doh.gov.za
Teléfono: 1.571.227.8600
Fax: 1.571.227.8601
URL: http://www.pfscm.org
Teléfono: 503.2248.8800
Fax: 503.2248.8899
Correo electrónico: info.sgsica@sica.int
URL: http://www.sica.int/
Teléfono: 45.3546.7000
Fax: 45.3546.7018
Correo electrónico: accessrh@unfpa.org
URL: http://www.unfpa.org/public/supplies
IC
Los productos regulados por el control internacional de narcóticos se identifican con las
siglas (IC) después de la descripción.
Nomenclatura
Se han utilizado la denominación común internacional (INN) como la lista de los
medicamentos incluidos en esta Guía. Si no se asigna un INN, entonces se emplea el
nombre genérico más común. Las formas de dosificación de medicamentos indicadas
suelen ser las que figuran en la 19a Lista Modelo de Medicamentos Esenciales de la
Organización Mundial de la Salud (OMS) (revisada en abril de 2015), y que se puede ver
en http://www.who.int/medicines.
Vía de administración
Las vías de administración se codifican en la forma siguiente:
Tipo de producto Código
Condones COND
Dispositivo intrauterino (DIU) IUD
Medicinas de uso local (líquidos, polvos,
cremas, ungüentos) TOP
Medicinas inyectables INJ
Medicinas para inhalación INH
Medicinas por uso nasal y de la garganta N/T
Medicinas subcutáneas S/C
Preparaciones vaginales VAG
Preparaciones para los ojos OPHT
Preparaciones para los oídos OTIC
Soluciones intravenosas IV
Supositorios/enemas/ungüentos rectales RECT
Tabletas/cápsulas/líquidos de vía oral PO
Fuente
La lista de fuentes de precios puede verse en la página S-9.
Paquetes
Los proveedores y compradores proporcionan los tamaños de los paquetes.
WHO LME
La columna “WHO EML” indica si el producto está incluido en la Lista Modelo OMS de
Medicamentos Esenciales de 2015. Identificamos cinco categorías en la Guía Internacional de
Indicadores de Precios de Medicamentos:
E = En la lista básica de la OMS, en la misma forma y potencia de dosificación
C = En la lista complementaria de la OMS, en la misma forma y potencia de
dosificación
P = En la lista de la OMS, pero en una presentación diferente (forma y/o potencia
de dosificación diferente)
T = No está en la lista de la OMS, pero puede ser una alternativa para un producto
listado como un ejemplo de grupo terapéutico
N = No está en la lista modelo de la OMS
Código ATC
El código ATC es el código de clasificación anatómica-terapéutica-química asignado por el
Collaborating Centre for Drug Statistics Methodology de la OMS. El sistema ATC/DDD es una
Precio mediano
Cuando se use la Guía para hacer comparaciones con precios locales, o para calcular el valor
total de una lista de adquisición, un precio promedio puede ser útil. Básicamente hay dos clases
de precios promedio que podrían usarse—el precio medio y el precio mediano. El precio medio
es el promedio simple de todos los precios mostrados para un medicamento; los valores se
suman y luego se dividen entre la cantidad de valores.
Sin embargo, surge un problema cuando uno o dos precios son mucho más altos o más bajos
que los demás en un medicamento determinado. Estos “valores extremos” producen una
desviación en el valor medio y lo hacen menos representativo. Por ejemplo, en una serie de siete
valores, tales como $1, $2, $2, $3, $5, $16 y $20, todos los valores suman $49, y dividiendo este
número entre siete se obtiene un valor medio de $7. Para fines de comparación o de estimados,
es probable que este promedio sea demasiado alto debido a los dos precios mucho más altos
que los demás de la serie. Para evitar este riesgo, usamos el precio mediano.
El precio mediano es un tipo de promedio; es el valor que divida una serie de valores a la mitad
cuando la serie se pone en orden ascendente. Esto probablemente sea un método más útil para
estimar los precios futuros reales (o para hacer comparaciones con precios locales) cuando
exista una distribución sesgada.
Si hay un número impar de valores en la serie, como el ejemplo anterior, el valor mediano es el
valor del medio en la serie ($3 en el ejemplo anterior). Cuando una serie contiene un número
par de valores, como en la serie $1, $3, $4, $6, $14 y $20, el precio mediano se calcula
promediando los dos valores del medio. En este ejemplo, el precio mediano es el promedio de
$4 y $6, o sea, $5. Nuevamente, es probable que esto se aproxime más a la realidad para la
comparación o estimación, que la media aritmética de $8 ($48 dividido entre 6).3
Proporción máxima/mínima
La proporción máxima/mínima (high/low) compara el precio unitario más alto con el precio
unitario más bajo. Por ejemplo, una proporción máxima/mínima de tres significa que el precio
unitario más alto es tres veces mayor que el precio unitario más bajo.
2
Tomado del sitio del Collaborating Centre for Drug Statistics Methodology de la OMS en la Web en http://www.whocc.no/
atcddd/.
3
Para ver más discusiones sobre el tema, ver Statistics without Tears—A Primer for Non-Mathematicians, por Derek
Rowntree (Nueva York: Charles Scribner’s Sons, 1981), pp. 41–45.
IC
Los productos regulados por el control internacional de narcóticos se identifican con las
siglas (IC) después de la descripción.
Nomenclatura
Se han utilizado las denominaciones comunes internacionales (INN) como la lista de los
medicamentos incluidos en esta Guía. Si no se asigna un INN, entonces se emplea el
nombre genérico más común. Las formas de dosificación de los medicamentos indicadas
generalmente son las que figuran en la 19a. Lista Modelo OMS de Medicamentos
Esenciales (revisada en abril de 2015), y que se puede ver en http://www.who.int/
medicines.
Vía de administración
Las vías de administración se codifican en la forma siguiente:
Tipo de producto Código
Condones COND
Dispositivo intrauterino (DIU) IUD
WHO LME
La columna “WHO EML” indica si el producto está incluido en la Lista Modelo OMS de
Medicamentos Esenciales de 2015. Identificamos cinco categorías en la Guía Internacional de
Indicadores de Precios de Medicamentos:
E = En la lista básica de la OMS, en la misma forma y potencia de dosificación
C = En la lista complementaria de la OMS, en la misma forma y potencia de
dosificación
P = En la lista de la OMS, pero en una presentación diferente (forma y/o potencia
de dosificación diferente)
T = No está en la lista de la OMS, pero puede ser una alternativa para un producto
listado como un ejemplo de grupo terapéutico
N = No está en la lista modelo de la OMS
Número de proveedores/compradores
El número de proveedores o compradores que ofrecen este producto.
Precio mediano
Cuando se use la Guía para hacer comparaciones con precios locales, o para calcular el valor
total de una lista de adquisición, un precio promedio puede ser útil. Básicamente hay dos clases
de precios promedio que podrían usarse—el precio medio y el precio mediano. El precio medio
es el promedio simple de todos los precios mostrados para un medicamento; los valores se
suman y luego se dividen entre el número de valores.
Sin embargo, surge un problema cuando uno o dos precios son mucho más altos o más bajos
que los demás en un medicamento determinado. Estos “valores extremos” producen una
desviación en el valor medio y lo hacen menos representativo. Por ejemplo, en una serie de
siete valores, tales como $1, $2, $2, $3, $5, $16 y $20, todos los valores suman $49, y dividiendo este
Proporción máxima/mínima
La proporción máxima/mínima (high/low) compara el precio unitario más alto con el precio
unitario más bajo. Por ejemplo, una proporción máxima/mínima de tres significa que el precio
unitario más alto es tres veces mayor que el precio unitario más bajo.
4
Para ver más discusiones sobre el tema, ver Statistics without Tears—A Primer for Non-Mathematicians, por Derek Rowntree
(Nueva York: Charles Scribner´s Sons, 1981), pp. 41–45.
IC
Los productos regulados por el Control Internacional de Narcóticos se identifican con
las siglas (IC) después de la descripción.
Nomenclatura
Se han utilizado las denominaciones comunes internacionales (INN) como la lista de los
medicamentos incluidos en esta Guía. Si no se asigna un INN, entonces se emplea el
nombre genérico más común. Las formas de dosificación de medicamentos indicadas
suelen ser las que figuran en la 19a. Lista Modelo de Medicinas Esenciales de la
Organización Mundial de la Salud (revisada en abril de 2015), y que se puede ver en
http://www.who.int/medicines.
WHO LME
La columna “WHO EML” indica si el producto está incluido en la Lista Modelo OMS de
Medicamentos Esenciales de 2015. Identificamos cinco categorías en la Guía Internacional de
Indicadores de Precios de Medicamentos:
E = En la lista básica de la OMS, en la misma forma y potencia de dosificación
C = En la lista complementaria de la OMS, en la misma forma y potencia de
dosificación
P = En la lista de la OMS, pero en una presentación diferente (forma y/o potencia
de dosificación diferente)
T = No está en la lista de la OMS, pero puede ser una alternativa para un producto
listado como un ejemplo de grupo terapéutico
N = No está en la lista modelo de la OMS
Precio unitario
El usuario debe calcular su precio unitario dividiendo el precio del paquete entre el número de
unidades que contiene el paquete. Se indican las unidades de comparación empleadas en la
Guía para cada producto con objeto de asegurar que los precios se comparen sobre una base
equivalente.
5
Para ver más discusiones sobre el tema, ver Statistics without Tears—A Primer for Non-Mathematicians, por Derek Rowntree
(Nueva York: Charles Scribner´s Sons, 1981), pp. 41–45.
Préface F-3
Prière de noter qu’une version électronique de l’Indicateur de Prix Internationaux des
Médicaments est donnée au Centre de Ressources Electroniques de MSH à http://
erc.msh.org/priceguide.
Pour de plus amples informations ou pour faire des commentaires ou suggestions sur la
présentation ou le contenu de la présente publication, prière de nous contacter à l’adresse
suivante:
Center for Pharmaceutical Management Policy, Access and Use Unit
Management Sciences for Health Department of Essential Medicines and Health
4301 North Fairfax Drive, Suite 400 Products
Arlington, VA 22203-1627 USA World Health Organization
Téléphone: 1.703.524.6575 Avenue Appia 20
Fax: 1.703.524.7898 CH-1211 Geneva 27
Courrier électronique: cpm@msh.org Switzerland
Courrier électronique: forteg@who.int
Tout changement des taux de change peut influencer nettement le coût. Le taux le plus actuel
au moment de votre analyse devrait toujours être utilisé lorsqu’on calcule les coûts des
médicaments.
Assurance de la qualité
Nous demandons que tous les fournisseurs compris dans l’Indicateur de Prix Internationaux
des Médicaments remplissent un questionnaire sur l’assurance de la qualité. Ce questionnaire
obligatoire a pour objet d’aider à vérifier que les prix du Guide proviennent de fournisseurs de
bonne réputation qui disposent de méthodes établies d’assurance de la qualité. Les 28 questions
traitent de divers aspects dont l’inspection, les tests, l’assurance de la qualité, les autorisations,
les rappels, les procédures de contrôle de la qualité, les normes et la documentation. Certes,
cette condition confère une certaine assurance des méthodes de contrôle de la qualité, mais elle
ne garantit pas forcément la qualité des produits indiqués dans les listes. Des exemplaires de
questionnaires peuvent être obtenus sur demande auprès de Management Sciences for Health.
Les sources des prix comprises dans le Guide n’ont été examinées qu’en mesure du caractère
complet des documents fournis à cet effet. Un tel dépistage ne constitue nullement une étude
approfondie de la qualité du produit. Le fait qu’elles soient incluses au Guide ne représente pas
une qualification préalable ou une approbation de la part de MSH et de l’OMS.
Le système ATC/DDD1
Les données sur l’utilisation de médicaments revêtent une importance capitale dans le cycle de
la qualité des soins et sont essentielles pour gérer les politiques relatives à l’approvisionnement,
à la fixation des prix, au coût et à l’utilisation des médicaments. Les méthodologies du système
de classification anatomique-thérapeutique-chimique (ATC) et de dose journalière définie
(defined daily dose - DDD) sont utiles pour suivre et comparer les tendances au niveau des
coûts, mais doivent être utilisées avec circonspection. En effet, on utilise mal le système si l’on
fonde des décisions détaillées de remboursement, de référence de groupe thérapeutique et autres
décisions spécifiques concernant les prix sur les systèmes ATC et DDD.
Le but du système ATC/DDD est de servir d’outil pour la recherche sur l’utilisation des
médicaments aux fins d’améliorer la qualité de l’utilisation des médicaments. Une composante
de ce système concerne la présentation et la comparaison de statistiques sur la consommation
des médicaments, aux niveaux international et autres.
Le Centre collaborateur de l’OMS pour la Méthodologie des Statistiques des Médicaments et le
Groupe de Travail de l’OMS cherchent à maintenir des codes ATC et DDD stables, dans le
temps, afin de pouvoir étudier les tendances au niveau de la consommation des médicaments
sans la complication de changements fréquents portés au système. En effet, on hésite beaucoup
à changer les classifications ou les DDD quand de tels changements sont demandés pour des
raisons qui ne sont pas reliées directement aux études sur la consommation des médicaments.
C’est la raison pour laquelle le système ATC/DDD en lui-même ne convient pas pour éclairer
les décisions sur les remboursements, la fixation de prix et la substitution thérapeutique.
La classification d’une substance dans le système ATC/DDD n’est pas une recommandation
d’utilisation et n’implique aucun jugement sur l’efficacité ou l’efficacité relative des
médicaments et groupes de médicaments.
Le texte dans cette section provient du site web du Centre collaborateur de l’OMS pour la Méthodologie des Statistiques des
1
Médicaments à http://www.whocc.no/atcddd/.
Frais de
Date de la Type de
Fournisseur Code manu- Détails
liste prix
tention
Les prix sont en vigueur jusqu’à la publication de la liste de prix revue. Les frais de
transport sont facturés individuellement selon les dépenses. Pour un emballage
MEDEOR/ septembre Départ usine
Action Medeor 1% spécial (caisses en bois), ils prélèvent 26 euros par caisse. Il y a un droit de
EU 2014 Tönisvorst
manutention minimum de 50 euros. Elle fournit des produits seulemennt au marché
non lucratif.
Départ usine
AMSTEL- janvier Les prix d'Amstelfarma sont donnés uniquement comme indication. Il n'y a pas de
Amstelfarma 0% Lelystad, The
FARM 2015 quantités de commande minimales ni de frais de service.
Netherlands
ASRAMES fournit ses services uniquement aux aux organisations de la RDC qui
DDP ou CIP
ASRAMES ASRAMES août 2014 0% ont été reconnus par le ministère de la Santé comme une institution de santé ou
Kinshasa
une ONG travaillant dans le secteur de la santé.
Durbin fournit des produits pharmaceutiques et des fournitures médicales aux
Départ usine médecins, pharmacies, hôpitaux, grossistes et détaillants en produits
F-9
Frais de
Date de la Type de
F-10
Fournisseur Code manu- Détails
liste prix
tention
Organisation à but non lucratif apportant un soutien aux soins de santé dans des
pays à revenus faibles et moyens, la Fondation IDA vise à améliorer l’accès aux
médicaments essentiels et fournitures médicales. IDA est une fondation
novembre Départ usine indépendante distribuant plus de 3000 produits dans 100 pays du monde entier.
IDA Foundation IDA 1,5%
2014 Amsterdam Pour les commandes de moins de 5 000 Euros, des frais de manutention de 3 %
sont demandés. Pour les commandes plus de 5 000 Euros, des frais de manutention
de 1,5 % sont demandés. Une commande minimale de 1500 Euros est exigée. Les
prix sont donnés à titre indicatif et peuvent changer.
FCA Lelystad,
janvier
IMRES IMRES 0% The La quantité minimale pour passer une commande est de 1250$ US.
2015
Netherlands
FCA
Medical Export novembre Gorinchem, Les prix sont donnés uniquement comme indication. Il n'y a pas de quantités de
MEG 0%
Group 2014 The commande minimales ni de frais de service.
Netherlands
Les prix de vente de MSD sont valables pour tous les établissements de santé
Medical Stores gouvernementales, les ONG approuvés, hôpitaux missionnaires, des hôpitaux de
MSD/
Organisme de
Frais de
développe- Date de la Type de
Code manu- Détails
ment inter- liste prix
tention
national
Les médicaments sont reçus gratuitement, sous forme de dons, mais ils sont également
disponibles aux fins d’achat par des gouvernements et des organisations qui souhaitent
profiter de la qualité, des prix et d'une assistance technique/soutien à la gestion des
médicaments fournie par l'entremise du Service d'achat direct du GDF. GDF réalise des
tests indépendants obligatoires sur chaque lot de médicaments qu’elle procure ainsi que la
pré-inspection de chaque commande qu’elle délivre pour s’assurer de la haute qualité des
Mécanisme produits. En plus du coût des médicaments, les charges pour le contrôle de qualité sont
global pour les payées par le client (ou bien payées par GDF en cas de don).
médicaments Départ usine,
contre la GDF 2014 0% l'usine de Pour faciliter la livraison efficace des produits, GDF utilise des agents transitaires. Des frais
tuberculose fournisseur supplémentaires pour les services des agents transitaires sont aussi ajoutés au coût de la
commande, qui inclut donc le coût des médicaments, les charges pour le contrôle de la
(Global TB Drug
qualité, et le fret. GDF envoie dans le pays une équipe d’experts en TB et en gestion de
Facility)
médicaments 4 mois après que les médicaments sont délivrés pour évaluer leur utilisation
et fournir l’assistance technique nécessaire. GDF ne charge pas de frais pour l’assistance
technique qu’elle fournit. Le GDF est un mécanisme visant à élargir l’accès aux médicaments
antituberculose de haute qualité, ainsi que la disponibilité de ces médicaments, pour faciliter
l’expansion à échelle mondiale de la stratégie de traitement sous surveillance directe
(DOTS), la stratégie recommandée internationalement pour lutter contre la tuberculose.
F-11
F-12
Organisme de
Frais de
développe- Date de la Type de
Code manu- Détails
ment inter- liste prix
tention
national
Le Fonds des Nations Unies pour la Population lance des appels d’offres pour l’achat de
Fonds des produits pour ses bureaux de terrain et pour le compte de clients dans plus de 168 pays,
Nations Unies septembre surtout dans le monde en développement. L'UNFPA ne travaille qu’avec des gouvernements
UNFPA 5% FOB
pour la Popu- 2014 et des organisations à but non lucratif. UNFPA demande des frais administratifs de 5% aux
lation (FNUAP) non-acheteurs de l’UNFPA. Il ya une exigence d'ordre minimum de 5000 $EU par unité. Les
prix sont donnés à titre indicatif et peuvent changer.
Valeur
Date de la Type de approx. de
Acheteur Code Détails
liste prix l'appel d'offre
($ américains)
The Public Procurement and Asset Disposal Board of
Botswana Public Procurement and janvier
BOTSWANA P/D P/D Botswana conduit des appels d'offres internationales et
Asset Disposal Board 2014
intérieurs et ouvertes et fermées de façon régulière.
La Sécurité Sociale du Costa Rica lance un appel d'offre
Caja Costarricense de Seguro international, annuel et ouvert, et négocie des contrats pour
CRSS 2014 DDU 126 million
Social des médicaments et des fournitures médicales pour ses
propres établissements.
DDP, La Clinton Health Access Initiative a contribué informations
Clinton Health Access Initiative CHAI 2014 EXW, ou P/D sur les prix de plusieurs partenaires qui travaillent ensemble
FOB pour étendre le traitement de la diarrhée.
Téléphone: 49.21.56.97.88.0
Fax: 49.21.56.97.88.88
Courrier électronique: info@medeor.org
URL: http://www.medeor.org
Téléphone: 49.21.56.97.88.0
Fax: 49.21.56.97.88.88
Courrier électronique: medeortz@bol.co.tz
URL: http://www.medeor.org
Amstelfarma
Nijverheidsweg 37
2102LK Heemstede
THE NETHERLANDS
Téléphone: 31-23-5484040
Courrier électronique: sales@amstelfarma.com
URL: http://www.amstelfarma.nl
Téléphone: 243.9.98.08.81.70
Courrier électronique: info@asrames.org
URL: www.asrames.com
Téléphone: 506.222.1878
Fax: 506.257.7004
Courrier électronique: farmaco@ccss.sa.cr
URL: http://www.info.ccss.sa.cr/
Téléphone: 617.774.0110
Courrier électronique: info@clintonhealthaccess.org
URL: http://www.clintonhealthaccess.org
Téléphone: 243.99.930.1015
URL: http://www.msh.org/our-work/projects/integrated-health-project
Téléphone: 809.518.1313
Courrier électronique: promesecal@promesecal.gov.do
URL: http://www.promesecal.gov.do/
Durbin PLC
180 Northolt Road
South Harrow
Middlesex
HA2 0LT
UNITED KINGDOM
Téléphone: 44.20.8660.2220
Fax: 44.20.8668.0751
Courrier électronique: cataloguesales@durbin.co.uk
URL: http://www.durbin.co.uk
Téléphone: 31.183.356.100
Fax: 31.183.356.122
Courrier électronique: info@meg.nl
URL: http://www.meg.nl
Téléphone: 255.27.250.9366
Fax: 255.27.254.4908
Courrier électronique: info@mems.or.tz
Téléphone: 41.22.791.3647
Fax: 41.22.791.4886
Courrier électronique: gdf@who.int
URL: http://www.globaldrugfacility.org ou http://www.stoptb.org/GDF
IDA Foundation
P.O. Box 37098
1030 AB Amsterdam
THE NETHERLANDS
Téléphone: 31.20.40.33.051
Fax: 31.20.40.31.854
Courrier électronique: info@idafoundation.org
URL: http://www.idafoundation.org
IMRES
P.O. Box 214
8200 AE Lelystad
THE NETHERLANDS
Téléphone: 31.320.296969
Fax: 31.320.296929
Courrier électronique: info@imres.nl
URL: http://www.imres.nl
Téléphone: 255.22.2860890
Fax: 255.22.2865814
Courrier électronique: info@msd.or.tz
URL: http://www.msd.or.tz
Téléphone: 254.020.3920.404
Fax: 254.020.3920.600
Courrier électronique: customerservice@meds.or.ke
URL: http://www.meds.or.ke
Téléphone: 264.61.233151
Fax: 264.61.238746
URL: http://www.cms-namibia.com
Téléphone: 758.452.5895
Fax: 758.453.0227
Courrier électronique: pps@oecs.org
URL: http://www.oecs.org/pps/
Téléphone: 51.14.315.6600
Courrier électronique: webmaster@minsa.gob.pe
URL: http://www.minsa.gob.pe/portada/
Téléphone: 27.12.312.0000
Fax: 27.12.326.4395
URL: http://www.doh.gov.za
Téléphone: 1.571.227.8600
Fax: 1.571.227.8601
URL: http://www.pfscm.org
Téléphone: 45.3546.7000
Fax: 45.3546.7018
Courrier électronique: accessrh@unfpa.org
URL: http://www.unfpa.org/public/supplies
Description du produit
La description du produit comprend le nom générique, l’efficacité, la présentation et la voie
d’administration. Si le produit a deux noms très utilisés (par exemple, vitamine C et acide
ascorbique), un nom apparaîtra entre crochets. Voir la Liste des Synonymes dans l’Annexe.
IC
Les produits sous contrôle international (narcotiques) sont identifiés avec (IC) à côté de
la description.
Nomenclature
La dénomination internationale est utilisée comme la liste des médicaments dans ce
Guide. Si elle n’a pas été donnée, c’est le nom générique le plus courant qui est utilisé.
Les présentations des médicaments indiqués sont généralement celles incluses dans la
19e liste modèle OMS des médicaments essentiels (revue en avril 2015), indiquée à
http://www.who.int/medicines.
Voie d’administration
Les voies d’administration sont codées de la manière suivante:
Type Code
Bandes de diagnostic DIAG
Comprimés/dragées/liquides oraux PO
Comprimés sublinguaux SL
Dispositif intra-utérin (Stérilet) IUD
Inhalation INH
Médicaments injectables INJ
Médicaments sous-cutanés S/C
Préparations auriculaires OTIC
Préparations nasales et pour la gorge N/T
Préparations ophtalmiques OPHT
Préparations vaginales VAG
Préservatifs (Condoms) COND
Produits dermatologiques (liquides, poudres,
crèmes et pommades) TOP
Solutés intraveineux IV
Suppositoires/lavement/pommade rectale RECT
Pas applicable N/A
Conditionnement
Les tailles du conditionnement sont données par les fournisseurs et les acheteurs.
LME de l’OMS
La colonne intitulée « WHO EML » indique si le produit fait partie de la Liste Modèle OMS de
Médicaments essentiels de 2015. Nous avons identifié cinq catégories dans l’Indicateur de Prix
Internationaux des Médicaments.
E = Appartient à la liste principale de l’OMS avec la même présentation et la même
efficacité/teneur
C = Appartient à la liste complémentaire de l’OMS avec la même présentation et la
même efficacité/teneur
P = Appartient à la liste de l’OMS, mais sous une présentation différente (forme et/
ou teneur différente)
T = Ne figure pas sur la liste de l’OMS, mais est un produit de remplacement pour
produit indiqué comme exemple d’un groupe thérapeutique
N = N’appartient pas à la liste modèle de l’OMS
Code ATC
Le code ATC est le code de classification anatomique-thérapeutique-chimique assigné par le
Centre collaborateur de l’OMS pour la Méthodologie des Statistiques des Médicaments. Le
système ATC/DDD sert d’outil pour la recherche en matière d’utilisation de médicaments afin
d’améliorer la qualité de l’utilisation des médicaments. Une des composantes de ce système
concerne la présentation et la comparaison de statistiques sur la consommation de
médicaments aux niveaux international et autres.
Prix médian
Un prix moyen peut être utile lorsqu’on utilise le Guide pour comparer avec des prix locaux
ou pour estimer la valeur totale d’une liste d’achat proposée. En fait, il existe deux types de
prix moyens qui peuvent être utilisés—le prix moyen et le prix médian. Le prix moyen est la
simple moyenne de tous les prix indiqués pour un médicament; les valeurs sont ajoutées et
divisées par le nombre de valeurs.
Toutefois, les choses sont plus difficiles lorsqu’un ou deux prix sont plus élevés ou plus faibles
que le reste pour un médicament donné. Ce prix moyen sera « faussé », ce qui le rend moins
représentatif. Par exemple, dans une série de sept valeurs, telle que $1, $2, $2, $3, $5, $16, $20, le
total de toutes les valeurs est de $49 et, quand on divise cette valeur par sept, on obtient un prix
moyen égal à $7. Aux fins de comparaison ou d’estimation, il est probable que cette moyenne
est trop élevée à cause des deux prix qui sont bien plus élevés que les autres dans la série. Pour
éviter ce risque, nous utilisons le prix médian.
Le prix médian est un type de prix moyen. C’est la valeur qui sépare au milieu une série de
valeurs quand la série est mise en ordre croissant. Ceci serait probablement une approche plus
valable pour estimer les prix futurs réels (ou pour comparer avec les prix locaux) lorsque la
distribution n'est pas directe.
S’il existe un nombre impair de valeurs dans cette série, comme dans l’exemple ci-dessus, la
valeur médiane est la valeur du milieu de la série ($3 dans notre exemple). Dans le cas d’un
nombre pair de valeurs dans une série, tel que $1, $3, $4, $6, $14, $20, la valeur médiane est
calculée en faisant la moyenne de la somme des deux valeurs du milieu de la série. Dans cet
exemple, la médiane est la moyenne de $4 et de $6, à savoir $5. Là aussi, c’est probablement
plus proche de la réalité aux fins de comparaison ou d’estimation que la moyenne arithmétique
de $8 ($48 divisé par 6).3
Ratio elevé/faible
Le ratio elevé/faible (« high/low ») compare le prix unitaire le plus élevé avec le prix unitaire
le plus faible. Par exemple, un ratio elevé/faible de 3 signifie que le prix unitaire le plus élevé
est trois fois supérieur au prix unitaire le plus faible.
2
Pris du site web du Centre collaborateur de l’OMS pour la Méthodologie des Statistiques des Médicaments à http://
www.whocc.no/atcddd/.
3
Pour de plus amples détails, voir Statistics Without Tears—A Primer for Non-Mathematicians, par Derek Rowntree (New York:
Charles Scribner’s Sons, 1981), pp. 41–45.
Description du produit
La description du produit comprend le nom générique, l’efficacité, le dosage et la voie
d’administration. Si le produit a deux noms très utilisés (par exemple, vitamine C et
acide ascorbique), un nom apparaîtra entre crochets. Voir la Liste des Synonymes dans
l’Annexe.
IC
Les produits sous contrôle international (narcotiques) sont identifiés avec (IC) à côté de
la description.
Nomenclature
La dénomination internationale est utilisée comme la liste des médicaments dans ce
Guide. Si elle n’a pas été donnée, c’est le nom générique le plus courant qui est utilisé.
Les présentations des médicaments indiqués sont généralement celles incluses dans la
19e Liste modèle OMS des médicaments essentiels (revue en avril 2015), indiquée à
http://www.who.int/medicines.
Voie d’administration
Les voies d’administration sont codées de la manière suivante:
Type Code
Bandes et tests de diagnostic DIAG
Comprimés/dragées/liquides oraux PO
Comprimés sublinguaux SL
LME de l’OMS
La colonne intitulée « WHO EML » indique si le produit fait partie de la Liste Modèle OMS de
Médicaments essentiels de 2015. Nous avons identifié cinq catégories dans l’Indicateur de Prix
Internationaux des Médicaments.
E = Appartient à la liste principale de l’OMS avec la même présentation et la même
efficacité/teneur
C = Appartient à la liste complémentaire de l’OMS avec la même présentation et la
même efficacité/teneur
P = Appartient à la liste de l’OMS, mais sous une présentation différente (forme et/
ou teneur différente)
T = Ne figure pas sur la liste de l’OMS, mais est un produit de remplacement pour
produit indiqué comme exemple d’un groupe thérapeutique
N = N’appartient pas à la liste modèle de l’OMS
Nombre de fournisseurs/acheteurs
Le nombre de fournisseurs ou d’acheteurs offrant ce produit.
Prix médian
Un prix moyen peut être utile lorsqu’on utilise le Guide pour comparer avec des prix locaux ou
pour estimer la valeur totale d’une liste d’achat proposée. En fait, il existe deux types de prix
moyens qui peuvent être utilisés—le prix moyen et le prix médian. Le prix moyen est la simple
moyenne de tous les prix indiqués pour un médicament; les valeurs sont ajoutées et divisées
par le nombre de valeurs.
Toutefois, les choses sont plus difficiles lorsqu’un ou deux prix sont plus élevés ou plus faibles
que le reste pour un médicament donné. Ce prix moyen sera « faussé », ce qui le rend moins
représentatif. Par exemple, dans une série de sept valeurs, telle que $1, $2, $2, $3, $5, $16, $20, le
Ratio elevé/faible
Le ratio elevé/faible (« high/low ») compare le prix unitaire le plus élevé avec le prix unitaire le
plus faible. Par exemple, un ratio elevé/faible de 3 signifie que le prix unitaire le plus élevé est
trois fois supérieur au prix unitaire le plus faible.
Pour de plus amples détails, voir Statistics Without Tears—A Primer for Non-Mathematicians, par Derek Rowntree (New York:
4
Description du produit
La description du produit comprend le nom générique, l’efficacité, le dosage et la voie
d’administration. Si le produit a deux noms très utilisés (par exemple, vitamine C et acide
ascorbique), un nom apparaîtra entre crochets. Voir la Liste des Synonymes dans l’Annexe.
IC
Les produits sous contrôle international (narcotiques) sont identifiés avec (IC) à côté de
la description.
Nomenclature
La dénomination internationale est utilisée comme la liste des médicaments dans ce
Guide. Si elle n’a pas été donnée, c’est le nom générique le plus courant qui est utilisé.
Les présentations des médicaments indiqués sont généralement celles incluses dans la
19e liste modèle OMS des médicaments essentiels (revue en avril 2015), indiquée à
http://www.who.int/medicines.
LME de l’OMS
La colonne intitulée « WHO EML » indique si le produit fait partie de la Liste Modèle OMS de
Médicaments essentiels de 2015. Nous avons identifié cinq catégories dans l’Indicateur de Prix
Internationaux des Médicaments:
E = Appartient à la liste principale de l’OMS avec la même présentation et la même
efficacité/teneur
C = Appartient à la liste complémentaire de l’OMS avec la même présentation et la
même efficacité/teneur
P = Appartient à la liste de l’OMS, mais sous une présentation différente (forme et/
ou teneur différente)
T = Ne figure sur la liste de l’OMS, mais est un produit de remplacement pour
produit indiqué comme exemple d’un groupe thérapeutique
N = N’appartient pas à la liste modèle de l’OMS
Prix du conditionnement
L’espace en blanc ici permet à l’utilisateur d’indiquer le prix pour le conditionnement de
l’achat indiqué dans l’espace précédent.
Prix unitaire
L’utilisateur devrait calculer son prix unitaire en divisant le prix du conditionnement par la
taille du conditionnement. L’unité de comparaison utilisée dans ce Guide est indiquée pour
chaque produit pour vérifier que les prix sont comparés sur une base équivalente.
Pour de plus amples détails, voir Statistics Without Tears—A Primer for Non-Mathematicians, par Derek Rowntree (New York:
5
3. Choisir un des deux formulaires de comparaison des prix compris dans le Guide, en
fonction du type de prix que vous comparez. Les prix d'acheteurs incluent le transport et
conviendront mieux s'ils représentent une région du monde (et valeur d’appel d’offre)
semblable à la vôtre. Les prix des fournisseurs sont des prix FOB et départ usine et doivent
être ajustés pour refléter les frais habituels d’expédition, de manutention et d’assurance
dans votre situation.
4. Sur les formulaires de comparaison des prix, choisissez dans ce Guide, le produit qui se
rapproche le plus de votre produit. Si les prix que vous utilisez localement sont des prix
CIF et si vous avez choisi le formulaire de comparaison de l’acheteur, aucun ajustement
n’est nécessaire pour l’un ou l’autre de cet ensemble de prix.
Si les prix que vous utilisez localement sont des prix CIF et si vous avez choisi la liste de
comparaison du fournisseur, nous recommandons que les prix indiqués sur la liste du
fournisseur soient ajustés à la hausse pour refléter les différences entre CIF et départ
usine/FOB. Quand les prix sur cette liste sont FOB ou départ usine, il est raisonnable
d’ajouter 10% au prix de la liste pour le fret et l’assurance en fonction de la distance et du
mode de transport. Tout pourcentage standard demandé pour la manutention a été ajouté
aux prix de cette liste.
En cas de fluctuations importantes des taux de change, des ajustements de prix doivent
être faits pour refléter ces changements.
5. Une fois les prix du conditionnement soient ajustés pour refléter le fret, l’assurance et
autres coûts supplémentaires, diviser le prix du conditionnement par le nombre d’unité de
comparaison contenues dans le conditionnement du vendeur (par exemple, diviser le prix
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-1 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-2 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-3 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-4 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-5 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-6 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-7 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-8 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-9 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-10 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-11 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-12 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-13 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-14 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-15 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
Buyer PERU 100 TAB-CAP 14.51 0.1451 TABLETS, ILLUSTRATIVE PACK SIZE
Buyer SAFRICA 30 TAB-CAP 6.07 0.2024 TABLETS
Buyer MEMS 30 TAB-CAP 6.97 0.2323 TABLETS
Buyer Median Price/tab-cap=0.2024 High/Low Ratio=1.60
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-16 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-17 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
Buyer DOMREPUB 100 TAB-CAP 0.59 0.0059 BLISTER PACK TABLETS, ILLUSTRATIVE PACK SIZE
Buyer SUDANNHIF 100 TAB-CAP 24.93 0.2493 TABLETS, ILLUSTRATIVE PACK SIZE
Buyer Median Price/tab-cap=0.1276 High/Low Ratio=42.25
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-18 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-19 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-20 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-21 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
Buyer PERU 100 TAB-CAP 47.37 0.4737 TABLET, ILLUSTRATIVE PACK SIZE
Buyer SUDANNHIF 100 TAB-CAP 62.69 0.6269 TABLETS, ILLUSTRATIVE PACK SIZE
Buyer Median Price/tab-cap=0.5503 High/Low Ratio=1.32
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-22 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-23 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-24 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-25 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
Buyer SUDANNHIF 100 TAB-CAP 3.87 0.0387 TABLETS, ILLUSTRATIVE PACK SIZE
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-26 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-27 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
Buyer PERU 100 TAB-CAP 5.92 0.0592 TABLETS, ILLUSTRATIVE PACK SIZE
Buyer DOMREPUB 1 TAB-CAP 0.07 0.0700 BLISTER PACK CAPSULES
Buyer OECS/PPS 100 TAB-CAP 12.00 0.1200 CAPSULES
Buyer Median Price/tab-cap=0.0700 High/Low Ratio=2.03
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-28 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
Buyer PERU 100 TAB-CAP 5.38 0.0538 TABLET, ILLUSTRATIVE PACK SIZE
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-29 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-30 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-31 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-32 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-33 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-34 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-35 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-36 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
Buyer PERU 100 TAB-CAP 67.64 0.6764 TABLET, ILLUSTRATIVE PACK SIZE
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-37 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-38 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-39 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
Buyer DOMREPUB 100 TAB-CAP 0.25 0.0025 BLISTER PACK TABLETS, ILLUSTRATIVE PACK SIZE
Buyer PERU 100 TAB-CAP 0.59 0.0059 TABLETS, ILLUSTRATIVE PACK SIZE
Buyer SAFRICA 28 TAB-CAP 0.34 0.0120 TABLETS
Buyer Median Price/tab-cap=0.0059 High/Low Ratio=4.80
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-40 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-41 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-42 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-43 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
Buyer PERU 100 TAB-CAP 13.39 0.1339 TABLETS, ILLUSTRATIVE PACK SIZE
Buyer SAFRICA 250 TAB-CAP 37.83 0.1513 TABLETS
Buyer CRSS 100 TAB-CAP 26.84 0.2684 TABLETS
Buyer Median Price/tab-cap=0.1513 High/Low Ratio=2.00
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-44 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
FERROUS SALT (IRON=60-65 MG) 200 mg tab-cap (PO) Price/tab-cap 0.2 g E B03AA
Supplier UNFPA 1000 TAB-CAP 1.58 0.0016 SUGAR-COATED TABLETS, 60-65 MG FE
Supplier MEG 1000 TAB-CAP 2.13 0.0021 SULFATE, TABLETS
Supplier ASRAMES 1000 TAB-CAP 2.28 0.0023 TABLETS, SULFATE
Supplier IMRES 1000 TAB-CAP 2.50 0.0025 SUGAR-COATED TABLETS, SULFATE
Supplier DURBIN 1000 TAB-CAP 2.91 0.0029 TABLETS
Supplier MEDS 1000 TAB-CAP 2.96 0.0030 TABLETS, SULFATE
Supplier AMSTELFAR 5000 TAB-CAP 14.85 0.0030 65 MG IRON, COATED TABLET
Supplier IDA 1000 TAB-CAP 2.99 0.0030 COATED TABLETS
Supplier MEDEOR/EU 5000 TAB-CAP 24.12 0.0048 SULFATE TABLETS
Supplier Median Price/tab-cap=0.0029 High/Low Ratio=3.00
Buyer MEMS 1000 TAB-CAP 4.20 0.0042 TABLETS
Buyer PERU 100 TAB-CAP 1.09 0.0109 TABLETS, ILLUSTRATIVE PACK SIZE
Buyer OECS/PPS 1000 TAB-CAP 21.00 0.0210 60 MG IRON SULFATE TABLETS
Buyer Median Price/tab-cap=0.0109 High/Low Ratio=5.00
FERROUS SALT+FOLIC ACID (IRON=60 MG) 200 mg+0.4mg tab-cap Price/tab-cap 0.2 g E B03AD
(PO)
Supplier UNFPA 1000 TAB-CAP 2.21 0.0022 COATED TABLETS
Supplier MEG 1000 TAB-CAP 2.50 0.0025 SUGAR-COATED TABLETS
Supplier IMRES 1000 TAB-CAP 2.95 0.0030 COATED TABLETS, SULFATE
Supplier IDA 1000 TAB-CAP 3.20 0.0032 TABLETS
Supplier MEDEOR/TZ 1000 TAB-CAP 4.32 0.0043 TABLETS
Supplier MEDEOR/EU 5000 TAB-CAP 30.34 0.0061 COATED TABLETS
Supplier Median Price/tab-cap=0.0031 High/Low Ratio=2.77
Buyer PERU 100 TAB-CAP 3.40 0.0340 TABLETS, ILLUSTRATIVE PACK SIZE
FERROUS SALT+FOLIC ACID (IRON=60 MG) 200+0.25 mg tab-cap Price/tab-cap 0.2 g P B03AD
(PO)
Supplier ASRAMES 1000 TAB-CAP 2.10 0.0021 TABLETS, FERROUS SULFATE
Supplier DURBIN 1000 TAB-CAP 2.65 0.0027 TABLETS
Supplier IMRES 1000 TAB-CAP 2.75 0.0027 COATED TABLETS, SULFATE
Supplier MEG 1000 TAB-CAP 2.75 0.0027 SULFATE, TABLETS
Supplier MEDEOR/TZ 1000 TAB-CAP 5.76 0.0058 TABLETS
Supplier MSD/TANZ 1000 TAB-CAP 8.58 0.0086 TABLETS
Supplier Median Price/tab-cap=0.0027 High/Low Ratio=4.10
Buyer DRC/IHP 1000 TAB-CAP 2.34 0.0023 TABLETS
Buyer MEMS 1000 TAB-CAP 5.16 0.0052 TABLETS
Buyer OECS/PPS 300 TAB-CAP 7.22 0.0241 TABLETS
Buyer Median Price/tab-cap=0.0052 High/Low Ratio=10.48
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-45 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-46 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-47 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-48 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-49 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-50 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-51 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-52 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-53 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-54 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-55 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-56 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-57 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
Buyer SAFRICA 1 VIAL (10 ml) 2.40 0.2405 HUMAN, BIOSYNTHETIC, YEAST-DERIVATIVE
Buyer OECS/PPS 1 VIAL (10 ml) 4.80 0.4800
Buyer Median Price/ml=0.3603 High/Low Ratio=2.00
INSULIN, NEUTRAL SOLUBLE (REGULAR) 100 IU/ml vial (SC) Price/ml 40 IU E A10AB
Supplier MEDS 1 VIAL (10 ml) 4.37 0.4368 ACTRAPID
Supplier DURBIN 1 VIAL (10 ml) 7.71 0.7707
Supplier MEDEOR/TZ 1 VIAL (10 ml) 9.96 0.9960
Supplier ASRAMES 1 BOTT (10 ml) 10.61 1.0610
Supplier Median Price/ml=0.8834 High/Low Ratio=2.43
Buyer DOMREPUB 1 VIAL (10 ml) 2.39 0.2390
Buyer OECS/PPS 1 VIAL (10 ml) 4.80 0.4800
Buyer MEMS 1 VIAL (10 ml) 5.04 0.5037 HUMAN
Buyer SAFRICA 1 CRTDGS (3 ml) 2.65 0.8839
Buyer Median Price/ml=0.4919 High/Low Ratio=3.70
INSULIN, ZINC SUSP (LENTE) 100 IU/ml vial (SC) Price/ml 40 IU E A10AE
Supplier ASRAMES 1 BOTT (10 ml) 11.14 1.1140
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-58 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-59 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-60 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-61 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-62 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-63 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-64 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
Buyer SUDANNHIF 100 TAB-CAP 2.35 0.0235 TABLETS, ILLUSTRATIVE PACK SIZE
Buyer OECS/PPS 28 TAB-CAP 2.70 0.0964 SCORED TABLETS
Buyer Median Price/tab-cap=0.0600 High/Low Ratio=4.10
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-65 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-66 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
Buyer PERU 100 TAB-CAP 0.97 0.0097 TABLETS, ILLUSTRATIVE PACK SIZE
Buyer DOMREPUB 1 TAB-CAP 0.01 0.0100 BLISTER PACK TABLETS
Buyer SAFRICA 30 TAB-CAP 0.61 0.0202 TABLETS
Buyer OECS/PPS 30 TAB-CAP 0.73 0.0243 TABLETS
Buyer SUDANNHIF 100 TAB-CAP 7.64 0.0764 TABLET, ILLUSTRATIVE PACK SIZE
Buyer Median Price/tab-cap=0.0202 High/Low Ratio=7.88
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-67 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-68 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-69 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-70 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-71 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-72 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-73 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
MORPHINE SULFATE (SLOW RELEASE) 100 mg tab-cap (PO) Price/tab-cap 0.1 g E N02AA01
Buyer SAFRICA 60 TAB-CAP 48.32 0.8054 TABLETS
MOSQUITO NET, 1-PERSON, LLIN (70 X 180 X 150 CM) net (N/A) Price/each N V07A
Supplier DURBIN 25 EACH 154.13 6.1654 PERMANET
MOSQUITO NET, 2-PERSON, IMPREGNATED (130 X 180 X 150 CM) Price/each N V07A
net (N/A)
Supplier MEDEOR/TZ 1 EACH 5.39 5.3940
MOSQUITO NET, 2-PERSON, LLIN (130 X 180 X 150 CM) net Price/each N V04C
(N/A)
Supplier IDA 1 EACH 3.40 3.4036
MOSQUITO NET, FAMILY, IMPREGNATED (190 X 180 X 150 CM) net Price/each N V07A
(N/A)
Supplier MEDEOR/TZ 1 EACH 5.34 5.3430
MOSQUITO NET, FAMILY, LLIN (190 X 180 X 150 CM) net (N/A) Price/each N V04C
Supplier IDA 1 EACH 4.03 4.0288
Supplier ASRAMES 1 EACH 6.80 6.8000
Supplier IMRES 1 EACH 7.00 7.0000
Supplier DURBIN 25 EACH 203.80 8.1520 PERMANET
Supplier Median Price/each=6.9000 High/Low Ratio=2.02
MOSQUITO NET, FAMILY, NON-IMPREG. (190 X 180 X 150 CM) net Price/each N V07A
(N/A)
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-74 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
MOSQUITO NET, IMPREGNATED (100 X 180 X 150 CM) net (N/A) Price/each N V04C
Supplier MEDEOR/TZ 1 EACH 4.49 4.4850
MOSQUITO NET, IMPREGNATED (160 X 180 X 150 CM) net (N/A) Price/each N V04C
Supplier MEDEOR/TZ 1 EACH 5.46 5.4600
MOSQUITO NET, LLIN (160 X 180 X 150 CM) net (N/A) Price/each N
Supplier ASRAMES 1 EACH 4.48 4.4800
Supplier IDA 1 EACH 5.70 5.6958 75 DENIER
Supplier Median Price/each=5.0879 High/Low Ratio=1.27
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-75 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
Buyer PERU 100 TAB-CAP 2.14 0.0214 TABLETS, ILLUSTRATIVE PACK SIZE
Buyer DOMREPUB 1 TAB-CAP 0.09 0.0900 BLISTER PACK
Buyer Median Price/tab-cap=0.0557 High/Low Ratio=4.21
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-76 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
Buyer DOMREPUB 100 TAB-CAP 0.25 0.0025 BLISTER PACK TABLETS, ILLUSTRATIVE PACK SIZE
Buyer SUDANNHIF 100 TAB-CAP 7.48 0.0748 TABLETS, ILLUSTRATIVE PACK SIZE
Buyer Median Price/tab-cap=0.0387 High/Low Ratio=29.92
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-77 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-78 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-79 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-80 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
ORS+ZINC CO-PACK (1-LT PACKET ORS+1 TAB ZINC) 1 ORS+20 mg Price/each EP A07CA
each (PO)
Buyer CHAI 1 EACH 0.48 0.4800 NIGERIA (FIDSON), SCORED, DISPERSIBLE, FLAVORED TAB,EXW
Buyer CHAI 1 EACH 0.58 0.5800 NIGERIA (OLPHARM), SCORED DISPERSIBLE TAB, FLAVORED,EXW
Buyer CHAI 1 EACH 0.91 0.9100 NIGERIA (CHI), SCORED DISPERSIBLE TAB, FLAVORED, EXW
Buyer Median Price/each=0.5800 High/Low Ratio=1.90
ORS+ZINC CO-PACK (2 1-LT ORS PACKETS+1 TAB ZINC) 2 ORS+20 Price/each EP A07CA
mg each (PO)
Buyer CHAI 15 EACH 5.75 0.3833 NIGERIA (EMZOR), SCORED DISPERSIBLE TAB, FLAVORED, EXW
Buyer CHAI 1 EACH 0.80 0.8000 UGANDA (ASTRA PHARMA), SCORED DISPERSIBLE TAB, DDP
Buyer CHAI 1 EACH 0.80 0.8000 UGANDA (GITTOES), SCORED DISPERSIBLE TABLET, DDP
Buyer Median Price/each=0.8000 High/Low Ratio=2.09
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-81 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
P-AMINOSALICYLIC ACID (PAS) (60% W/W) 9.2 g granules (PO) Price/packet P J04AA
Supplier GDF 30 PACKET 34.50 1.1500
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-82 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-83 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-84 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
PENICILLIN, BENZYL (600 MG, PEN. G) 1M IU powder (INJ) Price/vial 3.6 g E J01CE01
Supplier ASRAMES 50 VIAL 2.94 0.0588
Supplier MEG 50 VIAL 3.42 0.0684
Supplier IDA 50 VIAL 3.61 0.0722
Supplier IMRES 50 VIAL 3.65 0.0730
Supplier MEDS 1 VIAL 0.08 0.0784
Supplier MEDEOR/EU 100 VIAL 7.88 0.0788
Supplier AMSTELFAR 50 VIAL 4.90 0.0980
Supplier DURBIN 50 VIAL 5.14 0.1028
Supplier Median Price/vial=0.0757 High/Low Ratio=1.75
Buyer DOMREPUB 1 VIAL 0.09 0.0900
Buyer PERU 1 VIAL 0.18 0.1766 WITH DILUENT
Buyer SAFRICA 1 VIAL 0.47 0.4710
Buyer OECS/PPS 1 VIAL 0.68 0.6800
Buyer Median Price/vial=0.3238 High/Low Ratio=7.56
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-85 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
PERMETHRIN (FOR MOSQUITO NET TREATMENT) 10% solution (N/A) Price/ml N P03AC04
Supplier DURBIN 1 BOTT (105 ml) 17.13 0.1631 WITH PLASTIC SHEET, PLASTIC BAG, PVC GLOVES
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-86 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-87 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
POTASSIUM CHLORIDE (KCL, 20 MEQ/15 ML) 10% vial (INJ) Price/ml 3 g P B05XA01
Supplier IMRES 50 AMP (10 ml) 20.00 0.0400 100 MG/ML
Supplier IDA 100 AMP (10 ml) 47.65 0.0477
Supplier Median Price/ml=0.0439 High/Low Ratio=1.19
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-88 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-89 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-90 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-91 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-92 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-93 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-94 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-95 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-96 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-97 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
SODIUM STIBOGLUCONATE (10% SB) 33% vial (INJ) Price/ml 0.85 g E P01CB02
Supplier IDA 1 VIAL (30 ml) 9.66 0.3218
Buyer PERU 100 TAB-CAP 7.77 0.0777 TABLETS, ILLUSTRATIVE PACK SIZE
Buyer SUDANNHIF 100 TAB-CAP 26.27 0.2627 TABLETS, ILLUSTRATIVE PACK SIZE
Buyer Median Price/tab-cap=0.1702 High/Low Ratio=3.38
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-98 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-99 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-100 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-101 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-102 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
TEST, GLUCOSE METER (ON CALL PLUS) each (DIAG) Price/each N V04C
Supplier MEDEOR/TZ 1 EACH 19.35 19.3530
TEST, GLUCOSE METER STRIPS (FOR ON CALL PLUS) test (DIAG) Price/strip N V04C
Supplier MEDEOR/TZ 50 STRIPS 14.40 0.2880
Supplier MEDS 50 STRIPS 16.02 0.3203
Supplier Median Price/strip=0.3042 High/Low Ratio=1.11
TEST, GLUCOSE METER STRIPS (FOR SD CHECK GOLD) each (DIAG) Price/each N
Supplier IDA 50 STRIPS (1 EACH) 18.96 0.3793
TEST, HEPATITIS C, HCVSCAN (TM) (RAPID TEST) test (DIAG) Price/test N V04CX
Supplier MEDEOR/TZ 50 TEST 52.08 1.0416
Supplier IDA 100 TEST 465.67 4.6567
Supplier Median Price/test=2.8492 High/Low Ratio=4.47
Buyer DRC/IHP 100 TEST 263.33 2.6333
TEST, HIV 1+2 SD BIOLINE 3.0 (TM) test (DIAG) Price/test N V04CX
Supplier MEDEOR/TZ 25 TEST 42.00 1.6800 KIT
TEST, HIV 1+2 STAT PAK (TM) test (DIAG) Price/test N V04CX
Supplier IDA 20 TEST 55.71 2.7854
TEST, HIV 1+2+O AG/AB MUREX (TM) test (DIAG) Price/test N V04CX
Supplier IDA 96 TEST 259.79 2.7061
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-103 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-104 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
TEST, SYPHILIS (VDRL CARBON ANTIGEN FORTRESS) bott (DIAG) Price/ml N V04CX
Supplier IDA 1 BOTT (5 ml) 9.52 1.9032
TEST, SYPHILIS SD BIOLINE 3.0 (TM) (RAPID TEST) test Price/test N V04CX
(DIAG)
Supplier IMRES 30 TEST 23.50 0.7833 KIT
Supplier MSD/TANZ 1 KIT (30 TEST) 36.42 1.2140
Supplier Median Price/test=0.9987 High/Low Ratio=1.55
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-105 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-106 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-107 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-108 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
Buyer SAFRICA 1 VIAL (1 DOSE) 10.77 10.7708 GROUP A & C, PLUS DILUENT
Buyer SAFRICA 1 VIAL (1 DOSE) 21.28 21.2817 1 DOSE AMP PLUS DILUENT
VALPROIC ACID (SLOW RELEASE) 200 mg tab-cap (PO) Price/tab-cap 1.5 g P N03AG01
Buyer OECS/PPS 100 TAB-CAP 17.55 0.1755 E.C. TABLETS
VALPROIC ACID (SODIUM VALPROATE) 200 mg/5 ml syrup (PO) Price/ml 1.5 g E N03AG01
Buyer SAFRICA 1 BOTT (300 ml) 9.99 0.0333
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-109 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-110 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-111 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-112 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-113 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
Buyer SUDANNHIF 100 TAB-CAP 1.81 0.0181 TABLETS, ILLUSTRATIVE PACK SIZE
Buyer OECS/PPS 100 TAB-CAP 4.00 0.0400 TABLETS, CRYSTALLINE
Buyer CRSS 100 TAB-CAP 7.50 0.0750 TABLETS
Buyer Median Price/tab-cap=0.0400 High/Low Ratio=4.14
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-114 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-115 International Drug Price Indicator Guide, 2014
List I: Products Sorted Alphabetically
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on list
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
A-116 International Drug Price Indicator Guide, 2014
List II: Products Sorted by
Therapeutic Category
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
5. ANTICONVULSANTS/ANTIEPILEPTICS
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
6.1.2. ANTIFILARIALS
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
6.4.2. ANTIRETROVIRALS
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
7. ANTIMIGRAINE MEDICINES
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
9. ANTIPARKINSONISM MEDICINES
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
15.1. ANTISEPTICS
15.2. DISINFECTANTS
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
16. DIURETICS
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
17.4. LAXATIVES
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
18.4. ESTROGENS
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
18.7. PROGESTOGENS
19.3. VACCINES
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
21.5. MYDRIATICS
22.1. OXYTOCICS
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO DEFINED
ITEM DESCRIPTION EML DAILY DOSE*
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on List
*The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. DDDs have not been established for pediatric use.
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Aluminium Hydr.+ Magnesium Hydr. 250+120 mg Tab-Cap P __________ ___________ _________/tab-cap 0.0056/tab-cap
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Artesunate+amodiaquine (3 Fixed Dose Combo Tabs) 100mg+270mg P __________ ___________ _________/treatmen 0.9280/treatmen
Tab-Cap
Artesunate+amodiaquine (3 Fixed Dose Combo Tabs) 25mg+67.5mg P __________ ___________ _________/treatmen 0.3906/treatmen
Tab-Cap
Artesunate+amodiaquine (3 Fixed Dose Combo Tabs) 50 mg+135 mg P __________ ___________ _________/treatmen 0.6363/treatmen
Tab-Cap
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Benzoic & Salicylic Acid (Whitfield's) 6% + 3% Ointment N __________ ___________ _________/g 0.0114/g
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Cromoglicic Acid (Sodium Cromoglicate) 2% Opht Drop N __________ ___________ _________/ml 0.1690/ml
Dextrose 2.5% In Sod. Chloride 0.45% Solution P __________ ___________ _________/ml 0.0018/ml
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Ferrous Salt (Iron=60-65 Mg) 200 mg Tab-Cap E __________ ___________ _________/tab-cap 0.0029/tab-cap
Ferrous Salt+folic Acid (Iron=60 Mg) 200 mg+0.4mg Tab-Cap E __________ ___________ _________/tab-cap 0.0031/tab-cap
Ferrous Salt+folic Acid (Iron=60 Mg) 200+0.25 mg Tab-Cap P __________ ___________ _________/tab-cap 0.0027/tab-cap
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Insulin, Isophane (Nph) 100 iu/ml Vial E __________ ___________ _________/ml 0.8834/ml
Insulin, Neut. Sol/isophane 30/70 (Human, Mixtard) 100 iu/ml P __________ ___________ _________/ml 0.4334/ml
Vial
Insulin, Neutral Soluble (Regular) 100 iu/ml Vial E __________ ___________ _________/ml 0.8834/ml
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Insulin, Zinc Susp (Lente) 100 iu/ml Vial E __________ ___________ _________/ml 1.1140/ml
Lamivudine+stavudine (Tablet For Oral Suspension) 60+12 mg Tab- N __________ ___________ _________/tab-cap 0.0577/tab-cap
Cap
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Lamivudine/zidovudine + Efavirenz (2 Tab L/z.+ 1 Tab Ef. Co- P __________ ___________ _________/tab-cap 0.1811/tab-cap
Pack) 150/300+600m Tab-Cap
Lamivudine/zidovudine + Nevirapine (1 Tab L/z. + 1 Tab N. Co- E __________ ___________ _________/tab-cap 0.1446/tab-cap
Pack) 150/300+200m Tab-Cap
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Lidocaine Hcl + Epinephrine Dental 2%+1:80000 Crtdgs E __________ ___________ _________/ml 0.2639/ml
Lidocaine Hcl 5% (in Dextrose 7.5%) Vial E __________ ___________ _________/ml 0.1641/ml
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Mosquito Net, 1-Person, Llin (70 X 180 X 150 Cm) Net N __________ ___________ _________/each 6.1654/each
Mosquito Net, 2-Person, Impregnated (130 X 180 X 150 Cm) Net N __________ ___________ _________/each 5.3940/each
Mosquito Net, 2-Person, Llin (130 X 180 X 150 Cm) Net N __________ ___________ _________/each 3.4036/each
Mosquito Net, Family, Impregnated (190 X 180 X 150 Cm) Net N __________ ___________ _________/each 5.3430/each
Mosquito Net, Family, Llin (190 X 180 X 150 Cm) Net N __________ ___________ _________/each 6.9000/each
Mosquito Net, Family, Non-Impreg. (190 X 180 X 150 Cm) Net N __________ ___________ _________/each 1.1400/each
Mosquito Net, Impregnated (100 X 180 X 150 Cm) Net N __________ ___________ _________/each 4.4850/each
Mosquito Net, Impregnated (160 X 180 X 150 Cm) Net N __________ ___________ _________/each 5.4600/each
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Mosquito Net, Llin (160 X 180 X 150 Cm) Net N __________ ___________ _________/each 5.0879/each
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Norethisterone+estradiol Cypionate (In Oil) 50mg+5mg/ml Vial N __________ ___________ _________/ml 1.9740/ml
Oral Rehydration Salts (Ors) 1 pkt/1 l Powder E __________ ___________ _________/packet 0.1068/packet
Oral Rehydration Salts (Ors) 1 pkt/500 ml Powder E __________ ___________ _________/packet 0.0532/packet
Ors+zinc Co-Pack (4 500ml Packets+10 Tabs Zinc) 4 ors+20 mg E __________ ___________ _________/each 0.5040/each
Each
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
P-Aminosalicylic Acid (pas) 60% w/w Granules P __________ ___________ _________/g 0.1249/g
P-Aminosalicylic Acid (pas) (60% W/w) 9.2 g Granules P __________ ___________ _________/packet 1.1500/packet
P-Aminosalicylic Acid (pas) (For Oral Solution) 5.52 g Powder P __________ ___________ _________/packet 1.3700/packet
Penicillin, Benzathine Benzyl (720 Mg Of Pen. G) 1.2m iu Powder P __________ ___________ _________/vial 0.1278/vial
Penicillin, Benzathine Benzyl (1.44 G Of Pen. G) 2.4m iu Powder E __________ ___________ _________/vial 0.2635/vial
Penicillin, Benzyl (600 Mg, Pen. G) 1m iu Powder E __________ ___________ _________/vial 0.0757/vial
Penicillin, Phenoxymethyl (Pen. V) 125 mg/5 ml Suspen P __________ ___________ _________/ml 0.0100/ml
Penicillin, Phenoxymethyl (Pen. V) 250 mg/5 ml Syrup E __________ ___________ _________/ml 0.0149/ml
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Penicillin, Procaine Benzyl (600 Mg Of Pen. G) 1m iu Powder E __________ ___________ _________/vial 0.0980/vial
Penicillin, Procaine Benzyl (1.8 G Of Pen. G) 3m iu Powder E __________ ___________ _________/vial 0.2164/vial
Penicillin, Procaine Benzyl (2.4 G Of Pen. G) 4m iu Powder P __________ ___________ _________/vial 0.2606/vial
Permethrin (For Mosquito Net Treatment) 10% Solution N __________ ___________ _________/ml 0.1631/ml
Potassium Chloride (Kcl, 20 Meq/15 Ml) 10% Vial P __________ ___________ _________/ml 0.0439/ml
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Sodium Chloride In Water (Normal Saline) 0.9% Solution E __________ ___________ _________/ml 0.0010/ml
Sodium Lactate Compound (Ringer's/hartmann's Sol.) Solution E __________ ___________ _________/ml 0.0011/ml
Sodium Stibogluconate (10% Sb) 33% Vial E __________ ___________ _________/ml 0.3218/ml
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Tenofovir Df+emtricitabine (Tdf+ftc) 300 mg+200mg Tab-Cap E __________ ___________ _________/tab-cap 0.2029/tab-cap
Tenofovir Disoproxil Fumerate (tdf) (Equiv.245mg Tenofovir E __________ ___________ _________/tab-cap 0.1335/tab-cap
Disopro) 300 mg Tab-Cap
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Test, Glucose Meter (Sd Check Gold) Each N __________ ___________ _________/each 53.8583/each
Test, Glucose Meter (On Call Plus) Each N __________ ___________ _________/each 19.3530/each
Test, Glucose Meter Strips (For Sd Check Gold) Each N __________ ___________ _________/each 0.3793/each
Test, Glucose Meter Strips (For On Call Plus) Test N __________ ___________ _________/strip 0.3042/strip
Test, Hepatitis B Hbsag Elisa (Version 3) Test N __________ ___________ _________/test 1.9970/test
Test, Hepatitis C, Hcvscan (tm) (Rapid Test) Test N __________ ___________ _________/test 2.8492/test
Test, Hiv 1+2 Instantchek (tm) Test N __________ ___________ _________/test 1.8755/test
Test, Hiv 1+2 Sd Bioline 3.0 (tm) Test N __________ ___________ _________/test 1.6800/test
Test, Hiv 1+2 Stat Pak (tm) Test N __________ ___________ _________/test 2.7854/test
Test, Hiv 1+2+o Ag/ab Murex (tm) Test N __________ ___________ _________/test 2.7061/test
Test, Hiv, Capillus Hiv-1/2 (tm) Test N __________ ___________ _________/test 2.6441/test
Test, Hiv, Determine Hiv-1/2 (tm) Test N __________ ___________ _________/test 1.2000/test
Test, Hiv, Unigold I/ii (tm) Test N __________ ___________ _________/test 3.1779/test
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Test, Malaria, P. Falciparum (First Response Ag Rapid Test) N __________ ___________ _________/test 0.6752/test
Test
Test, Malaria, P. Falciparum+p. Pan (First Response Ag Rapid N __________ ___________ _________/test 0.9947/test
Test) Test
Test, Syphilis (Vdrl Carbon Antigen Fortress) Bott N __________ ___________ _________/ml 1.9032/ml
Test, Syphilis Sd Bioline 3.0 (tm) (Rapid Test) Test N __________ ___________ _________/test 0.9987/test
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Aluminium Hydr.+ Magnesium Hydr. 250+120 mg Tab-Cap P __________ ___________ _________/tab-cap 0.0039/tab-cap
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Benzoic & Salicylic Acid (Whitfield's) 6% + 3% Ointment N __________ ___________ _________/g 0.0095/g
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Bupivacaine Hcl + Epinephrine (0.5% + 1:200,000) Vial N __________ ___________ _________/ml 0.0793/ml
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Dialysis Sol. Peritoneal W/ Dextrose 1.5% Solution C __________ ___________ _________/ml 0.0036/ml
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Ferrous Salt (Iron=60-65 Mg) 200 mg Tab-Cap E __________ ___________ _________/tab-cap 0.0109/tab-cap
Ferrous Salt+folic Acid (Iron=60 Mg) 200 mg+0.4mg Tab-Cap E __________ ___________ _________/tab-cap 0.0340/tab-cap
Ferrous Salt+folic Acid (Iron=60 Mg) 200+0.25 mg Tab-Cap P __________ ___________ _________/tab-cap 0.0052/tab-cap
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Glyceryl Trinitrate 0.4 mg/dose Nasal Spr E __________ ___________ _________/dose 0.0298/dose
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Immunoglobulin, Varicella Zoster (Human) 125 iu/ml Vial N __________ ___________ _________/vial 125.6500/vial
Insulin, Isophane (Nph) 100 iu/ml Vial E __________ ___________ _________/ml 0.3603/ml
Insulin, Neut. Sol/isophane 30/70 (Human, Mixtard) 100 iu/ml P __________ ___________ _________/ml 0.3603/ml
Vial
Insulin, Neutral Soluble (Regular) 100 iu/ml Vial E __________ ___________ _________/ml 0.4919/ml
Insulin, Neutral Soluble (Regular) 40 iu/ml Vial E __________ ___________ _________/ml 0.2600/ml
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Lidocaine Hcl + Epinephrine Dental 2%+1:80000 Crtdgs E __________ ___________ _________/ml 0.2334/ml
Lidocaine Hcl 5% (in Dextrose 7.5%) Vial E __________ ___________ _________/ml 3.6800/ml
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Morphine Sulfate (Slow Release) 100 mg Tab-Cap E __________ ___________ _________/tab-cap 0.8054/tab-cap
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Norethisterone+estradiol Cypionate (In Oil) 50mg+5mg/ml Vial N __________ ___________ _________/ml 4.3900/ml
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Oral Rehydration Salts (Ors) 1 pkt/1 l Powder E __________ ___________ _________/packet 0.0500/packet
Ors+zinc Co-Pack (1-Lt Packet Ors+1 Tab Zinc) 1 ors+20 mg Each E __________ ___________ _________/each 0.5800/each
Ors+zinc Co-Pack (2 1-Lt Ors Packets+1 Tab Zinc) 2 ors+20 mg E __________ ___________ _________/each 0.8000/each
Each
Ors+zinc Co-Pack (2 1-Lt Ors+10 Tabs Zinc) 2 ors+20 mg Each E __________ ___________ _________/each 0.4500/each
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Penicillin, Benzathine Benzyl (720 Mg Of Pen. G) 1.2m iu Powder P __________ ___________ _________/vial 0.2155/vial
Penicillin, Benzathine Benzyl (1.44 G Of Pen. G) 2.4m iu Powder E __________ ___________ _________/vial 0.2760/vial
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Penicillin, Benzyl (600 Mg, Pen. G) 1m iu Powder E __________ ___________ _________/vial 0.3238/vial
Penicillin, Phenoxymethyl (Pen. V) 125 mg/5 ml Suspen P __________ ___________ _________/ml 0.0069/ml
Penicillin, Phenoxymethyl (Pen. V) 250 mg/5 ml Syrup E __________ ___________ _________/ml 0.0071/ml
Penicillin, Procaine Benzyl (600 Mg Of Pen. G) 1m iu Powder E __________ ___________ _________/vial 0.1801/vial
Penicillin, Procaine Benzyl (2.4 G Of Pen. G) 4m iu Powder P __________ ___________ _________/vial 0.2330/vial
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Sodium Amidotrizoate (Meglumine Diatrizoate) 76% Vial E __________ ___________ _________/ml 0.4725/ml
Sodium Chloride In Water (Normal Saline) 0.9% Solution E __________ ___________ _________/ml 0.0010/ml
Sodium Lactate Compound (Ringer's/hartmann's Sol.) Solution E __________ ___________ _________/ml 0.0007/ml
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Sulfadoxine+pyrimethamine (250 Mg+12.5 Mg/5 Ml) 250+12mg/5ml C __________ ___________ _________/ml 0.0782/ml
Suspen
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Tenofovir Df+emtricitabine (Tdf+ftc) 300 mg+200mg Tab-Cap E __________ ___________ _________/tab-cap 0.2251/tab-cap
Tenofovir Disoproxil Fumerate (tdf) (Equiv.245mg Tenofovir E __________ ___________ _________/tab-cap 0.5411/tab-cap
Disopro) 300 mg Tab-Cap
Test, Brucella Melitensis Antigen (Rapid) Test N __________ ___________ _________/test 0.1897/test
Test, Hepatitis C, Hcvscan (tm) (Rapid Test) Test N __________ ___________ _________/test 2.6333/test
Test, Hiv, Capillus Hiv-1/2 (tm) Test N __________ ___________ _________/test 0.9828/test
Test, Hiv, Determine Hiv-1/2 (tm) Test N __________ ___________ _________/test 1.0699/test
Test, Hiv, Unigold I/ii (tm) Test N __________ ___________ _________/test 3.3696/test
Test, Malaria, P. Falciparum (First Response Ag Rapid Test) N __________ ___________ _________/test 0.6203/test
Test
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Valproic Acid (Sodium Valproate) 200 mg/5 ml Syrup E __________ ___________ _________/ml 0.0333/ml
Valproic Acid (Slow Release) 200 mg Tab-Cap P __________ ___________ _________/tab-cap 0.1755/tab-cap
Vitamin A (Retinol (25,000 Iu)) 7.5 mg Tab-Cap P __________ ___________ _________/tab-cap 0.0390/tab-cap
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Vitamin B1 (Thiamine Hcl) 100 mg/ml Ampoule P __________ ___________ _________/ml 0.2170/ml
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
WHO EML = <E>ssential, <C>omplementary, <P>resentation, <T>herapeutic group alternative, <N>ot on the list
Source: WHO Model List of Essential Medicines 19th edition (revised April 2015), from http://
www.who.int/medicines/publications/essentialmedicines/en/index.html
Fuente: La 19o Lista Modelo de Medicamentos Esenciales de la OMS (revisada abril 2015), de http://
www.who.int/medicines/publications/essentialmedicines/en/index.html
Source: La 19e liste modèle OMS des médicaments essentiels (revue en avril 2015) de http://www.who.int/
medicines/publications/essentialmedicines/en/index.html.
Since 1971, MSH has worked in more than 150 countries with policymakers, health profession-
als, and health care consumers to improve the quality, availability, and affordability of health
services. We work with governments, donors, nongovernmental organizations, and health
agencies to respond to priority health problems such as HIV & AIDS, tuberculosis, malaria,
maternal-child health, and reproductive health. Our publications and electronic products
augment our assistance in these technical areas.
MSH’s staff of more than 2,400 from over 70 nations work in its Medford, Massachusetts,
headquarters; offices in the Washington, DC, area; and more than 50 country offices. Through
technical assistance, research, training, and systems development, MSH is committed to
making a lasting difference in global health.
For more information about Management Sciences for Health, please visit our website at
www.msh.org.
About the MSH Center for Pharmaceutical
Management
MSH has more than 30 years of experience in establishing, managing, and evaluating pharma-
ceutical sector activities in developing countries. In 1983, the MSH Drug Management Program
(DMP) was established in recognition of the key role that pharmaceuticals play in delivering
high-quality health care in developing countries.
In 2001, the DMP was restructured as the Center for Pharmaceutical Management (CPM). The
center, building on the work of the DMP, remains committed to providing high-quality techni-
cal assistance and training in pharmaceutical management worldwide.
The key to MSH’s success in providing technical assistance in pharmaceutical management is
our proven ability to work closely with both senior- and operations-level personnel in develop-
ing countries, while maintaining strong working relationships with the many international
agencies and donors sponsoring our work. These donors include USAID, WHO, PAHO,
UNICEF, Danida, the World Bank, and foundations such as the Bill & Melinda Gates Founda-
tion and the Rockefeller Foundation.
CPM has nearly 700 staff members working out of its primary office in the Washington, D.C.,
area and other locations worldwide, together with a roster of more than 50 expert consultants,
who are available as required. For more information on CPM, please contact:
Management Sciences for Health
Center for Pharmaceutical Management
4301 N. Fairfax Drive, Suite 400
Arlington, VA 22203 USA
Telephone: 703.524.6575
Fax: 703.524.7898
E-mail: cpm@msh.org
Acerca de Management Sciences for Health
Management Sciences for Health (MSH) es una organización privada sin fines de lucro
dedicada a cerrar la brecha entre lo que se sabe acerca de los retos de salud pública de muchas
naciones y lo que se hace por resolverlos.
Desde 1971, MSH ha trabajado en más de 150 países, con personal de políticas, profesionales de
salud y consumidores de servicios de atención de salud para mejorar la calidad, la disponi-
bilidad y la accesibilidad financiera de los servicios de salud. Trabajamos con los gobiernos, los
donantes, las organizaciones no gubernamentales, y las agencias de salud para responder a los
problemas prioritarios de salud como el VIH & SIDA, la tuberculosis, el paludismo, la
supervivencia maternal-infantil y la salud reproductiva. Nuestros productos electrónicos y
publicaciones complementan nuestra asistencia en estas áreas técnicas.
El cuadro de MSH que suma más de 2400 personas de más de 70 naciones trabaja en su sede en
Cambridge, Massachusetts, oficinas en los alrededores de Washington, DC y más de 50 oficinas
en el terreno. A través de sus investigaciones, asistencia técnica, capacitación y desarrollo de
sistemas, MSH se compromete a hacer una diferencia duradera en la salud global.
Para más información sobre Management Sciences for Health, por favor visite nuestro sitio
web, www.msh.org.
Acerca del Centro de Gestión Farmacéutica de
MSH
MSH tiene más de 30 años de experiencia en el desarrollo, gerencia y evaluación de las
actividades del sector farmacéutico en los países en desarrollo. En 1983 creó su programa de
gestión farmacéutica (Drug Management Program, o DMP), por reconocer el papel esencial de los
medicamentos en proporcionar atención médica de calidad en los países en desarrollo.
En 2001 DMP se transformó en el actual Centro de Gestión Farmacéutica (Center for Pharmaceuti-
cal Management, o CPM), que continúa la labor iniciada por DMP a nivel mundial y su
dedicación a proporcionar asistencia técnica y capacitación de alta calidad sobre este tema.
El éxito de MSH en su asistencia técnica sobre la gestión farmacéutica, se debe a su demostrada
capacidad para colaborar estrechamente—tanto con el personal de alto nivel, como con el
personal operativo en los países en desarrollo—y mantener una sólida relación de trabajo con
las diversas organizaciones internacionales y donantes que patrocinan sus actividades. Estos
donantes incluyen USAID, OMS, OPS, UNICEF, Danida, el Banco Mundial y fundaciones como
la Bill & Melinda Gates y la Rockefeller.
CPM tiene cerca de 700 personas asignadas en su oficina principal en el área metropolitana de
Washington, D.C., y en otros lugares por todo el mundo, y cuenta con una lista de más de 50
consultores especializados, que prestan sus servicios cuando estos son necesarios. Para más
información sobre CPM, por favor comuníquese con:
Teléfono: 703.524.6575
Fax: 703.524.7898
Correo electrónico: cpm@msh.org
A propos de Management Sciences for Health
Management Sciences for Health (MSH) est une organisation internationale à but non lucratif,
qui cherche à combler l’écart entre ce que l’on connaît des énormes défis de santé publique qui
confrontent de nombreuses nations et ce que l’on fait pour les adresser.
Depuis 1971, MSH a travaillé dans plus de 150 pays avec des décideurs, des professionnels de la
santé et des clients des services de santé pour améliorer la qualité et la disponibilité des services
de santé, et pour en réduire le coût. Nous collaborons avec les gouvernements, les bailleurs au
fonds, les organisations non gouvernementales, et les agences de santé pour répondre aux
problèmes prioritaires de santé, tels que le VIH & SIDA, la tuberculose, le paludisme, la santé
maternel-enfantine, et la santé de la reproduction. Nos publications et nos produits
électroniques sont une forme supplémentaire d’assistance dans ces domaines techniques.
MSH emploie plus de 2400 personnes provenant de plus de 70 nations ; MSH a son siège à
Cambridge, dans le Massachusetts, et des bureaux dans les environs de Washington DC ainsi
que dans plus de 50 pays. En fournissant assistance technique, recherche, formation, et en
développant des systèmes, MSH s’engage à faire une différence durable dans la santé mondiale.
Pour plus d’information sur Management Sciences for Health, veuillez consulter notre site Web
à www.msh.org.
A propos du Centre MSH pour la Gestion des
Médicaments
MSH a plus de 30 années d’expérience en ce qui concerne la mise sur pied, la gestion et
l’évaluation d’activités du secteur pharmaceutique dans des pays en développement. En 1983,
le Programme de Gestion des Médicaments (DMP) de MSH était créé au regard de l’importance
cruciale que détiennent les produits pharmaceutiques dans la prestation de soins de santé de
qualité dans des pays en développement.
En 2001, le DMP était restructuré donnant naissance au Centre pour la Gestion des Médica-
ments (CPM). Le Centre, fidèle aux travaux du DMP, reste engagé à fournir une assistance
technique et formation de qualité en matière de gestion pharmaceutique dans le monde entier.
MSH sait apporter une assistance technique efficace en matière de gestion pharmaceutique car
nous sommes capables de travailler en étroite collaboration avec les cadres supérieurs et
opérationnels dans des pays en développement tout en maintenant de relations fortes de travail
avec les nombreuses organisations internationales et bailleurs de fonds parrainant nos activités.
Ces bailleurs comprennent l’USAID, l’OMS, l’OPS, l’UNICEF, Danida, la Banque mondiale et
des fondations telles que la Fondation Bill & Melinda Gates et la Fondation Rockefeller.
CPM compte-t-il près de 700 membres de personnel travaillant à partir de ses bureaux
principaux dans la région de Washington, DC, et d’autres endroits mondials de pair avec un
groupe de plus de 50 consultants hautement spécialisés intervenant de manière ponctuelle.
Pour plus d’information sur CPM, veuillez contacter :
Téléphone : 703.524.6575
Fax : 703.524.7898
Courrier électronique : cpm@msh.org
2014 Edition ISBN 0-913723-05-3
The 2014 edition of the International Drug Price Indicator Guide was produced with the World
Health Organization.
Working with authors from around the world, MSH has revised its seminal
publication on global pharmaceutical management. Its 52 updated chapters
provide an overview and specific suggestions for effectively managing
pharmaceutical systems. The publication includes six new chapters on
pharmacovigilance, traditional medicines, intellectual property, and other
cutting-edge topics. MDS-3 is available on CD-ROM and online at www.msh.org.